RNAi modulation of TGF-beta and therapeutic uses thereof

ABSTRACT

The present invention concerns methods of treatment using transforming growth factor beta (TGF-beta) modulators. More specifically, the invention concerns methods of treating disorders associated with undesirable TGF-beta signaling, by administering short interfering RNA which down-regulate the expression of TGF-beta, and agents useful therein.

CROSS-REFERENCE TO RELATED APPLICATION

This application claims the benefit of U.S. Provisional Application No. 60/782,829, filed Mar. 16, 2006, which is hereby incorporated by reference in its entirety.

TECHNICAL FIELD

The present invention concerns methods of treatment using transforming growth factor beta (TGF-beta) modulators. More specifically, the invention concerns methods of treating disorders associated with undesirable TGF-beta signaling, by administering short interfering RNA which down-regulate the expression of TGF-beta, and agents useful therein.

BACKGROUND

RNA interference or “RNAi” is a term initially coined by Fire and co-workers to describe the observation that double-stranded RNA (dsRNA) can block gene expression when it is introduced into worms (Fire et al., Nature 391:806-811, 1998). Short dsRNA directs gene-specific, post-transcriptional silencing in many organisms, including vertebrates, and has provided a new tool for studying gene function. RNAi has been suggested as a method of developing a new class of therapeutic agents. However, to date, these have remained mostly as suggestions with no demonstrate proof that RNAi can be used therapeutically.

Transforming growth factor-beta (TGF-beta) isoforms (-1, -2, & -3) are potent cytokines that act in autocrine and paracrine fashion to effect a broad spectrum of biological processes, including proliferation, differentiation, apoptosis, and extracellular matrix production. TGF-beta exerts its biological effects via binding to TGF-beta receptors (types I, II, & III). The local over-expression of TGF-beta in the kidney, liver, or lung mediates the pathophysiology observed in diabetic nephropathy, chronic liver disease, and pulmonary fibrosis, respectively. TGF-beta1 is up-regulated in patients with diabetic nephropathy (for both type 1 or type 2 diabetes) and in animal models of the disease. Antibodies to TGF-beta have been shown to prevent disease in a mouse genetic model of type 2 diabetes (db/db mouse) and antisense targeting a conserved sequence in TGF-beta RNA has been shown to prevent disease in a streptozotocin-diabetic mouse model.

About 100,000 diabetic patients per year are treated for kidney disease in U.S. with health costs of $5.1 billion per year in the U.S. Diabetic nephropathy is the leading cause of end-stage renal disease in the industrialized world. Almost 40% of all new patients with renal failure admitted to renal replacement programs in the U.S have diabetic kidney disease. Albuminuria, proteinuria, serum creatinine, as well as circulating TGF-beta1 plasma levels, can be used as markers for efficacy determination in therapeutic evaluation.

Liver disease affects all age groups and both genders. The condition can be acute or chronic. The major causes of liver diseases in the United States are viruses (hepatitis A, B, C) and alcohol abuse. However, congenital, autoimmune and drug-induced causes are also significant contributors to the origin of liver diseases. Liver diseases disturb hepatic functions as a result of destruction of functional liver tissue and development of fibrosis (scarring), which blocks blood flow through the liver and causes portal hypertension (pressure in the portal vein). Blood flow then seeks an alternative route, leading to dilated swollen veins (varices) in the esophagus that may hemorrhage. Liver disease and portal hypertension also alter kidney function by causing retention of salt and water (ascites), and can induce renal failure (hepatorenal syndrome) and altered mental state (coma). The primary cytokine involved in tissue scaring in chronic liver disease is TGF-beta1. Recently it has been shown in a rat model of liver fibrosis that blocking TGF-beta1 can lead to improvement in liver histology. Further, in chronic Hepatitis C patients who have responded to interferon alpha, decreased levels of TGF-beta1 are associated with improvements in liver fibrosis.

TGF-beta1 has also been implicated in Idiopathic Pulmonary Fibrosis. Similar to liver disease, the mechanisms of action of TGF-beta1 in pulmonary fibrosis involves both induction and inhibition of the degradation of extracellular matrix proteins, leading to the formation of scar tissue. TGF-beta1 mediated cell signaling, primarily at the local site of connective tissue, is anabolic and leads to pulmonary fibrosis and angiogenesis, strongly indicating that TGF-beta1 may be involved in the repair of tissue injury caused by burns, trauma, or surgery. Pulmonary fibrosis, also called Interstitial Lung Disease (ILD), is a broad category of lung diseases that includes more than 130 disorders which are characterized by scarring of the lungs. ILD accounts for 15% of the cases seen by pulmonologists. Some of the interstitial lung disorders include: Idiopathic pulmonary fibrosis, Hypersensitivity pneumonitis, Sarcoidosis, Eosinophilic granuloma, Wegener's granulomatosis, Idiopathic pulmonary hemosiderosis, and Bronchiolitis obliterans. In ILD, scarring or fibrosis occurs as a result of either an injury or an autoimmune process. Approximately 70% of ILD have no identifiable cause and are therefore termed “idiopathic pulmonary fibrosis.” Some of the known causes include occupational and environmental exposure, dust (silica, hard metal dusts), organic dust (bacteria, animal proteins), gases and fumes, drugs, poisons, chemotherapy medications, radiation therapy, infections, connective tissue disease, systemic lupus erythematosus, and rheumatoid arthritis. In its severest form, ILD can lead to death, which is often caused by respiratory failure due to hypoxemia, right-heart failure, heart attack, stroke, blood clot (embolism) in the lungs, or lung infection brought on by the disease.

The use of small interfering nucleic acid molecules targeting transforming growth factor beta (TGF-beta) genes provides a class of novel therapeutic agents that can be used in the treatment of various diseases and conditions associated with undesired TGF-beta signaling, including diabetic nephropathy, chronic liver disease, pulmonary fibrosis, hematopoietic reconstitution, and any other inflammatory, respiratory, autoimmune, and/or proliferative disease, condition, or trait that responds to the level of TGF-beta in a cell, subject or organism, and particularly idiopathic pulmonary fibrosis.

SUMMARY

The present invention is based on the in vitro demonstration that TGF-beta expression can be inhibited by iRNA agents, and the identification of potent iRNA agents from the TGF-beta gene that can reduce RNA levels and protein levels of TGF-beta in cells, and particularly in an organism. Based on these findings, the present invention provides specific compositions and methods that are useful in reducing TGF-beta mRNA levels and TGF-beta protein levels in cells in vitro as well as in a subject in vivo, e.g., a mammal, such as a human. These compositions are particularly useful in the manufacturing of pharmaceutical compositions for the treatment of, and ultimately in methods to treat, subjects having or at risk of developing a disease or disorder associated with undesired TGF-beta signaling such as, for example, idiopathic pulmonary fibrosis.

The present invention specifically provides methods of reducing the levels of a TGF-beta mRNA in a cell of a subject, or of TGF-beta protein secreted by a cell of a subject, comprising the step of administering an iRNA agent to said subject, wherein the iRNA agent comprises an antisense strand consisting of 15 to 30 nucleotides and having at least 15 or more contiguous nucleotides complementary to a mammalian TGF-beta mRNA, and a sense strand consisting of 15 to 30 nucleotides and having at least 15 or more contiguous nucleotides complementary to said antisense strand. Said iRNA agent may mediate the cleavage of a TGF-beta mRNA within the target sequence of an iRNA agent selected from the group of: AL-DP-6837 to AL-DP-6864 and AD-14419 to AD-14638. In one embodiment, said iRNA agent comprises 15 or more contiguous nucleotides from an iRNA agent selected from the group of: AL-DP-6837 to AL-DP-6864, AL-DP-6140 to AL-DP-6151, AL-DP-6262 to AL-DP-6277 and AD-14419 to AD-14638. In a further embodiment, said iRNA agent is one of the iRNA agents selected from the group of: AL-DP-6837 to AL-DP-6864, AL-DP-6140 to AL-DP-6151, AL-DP-6262 to AL-DP-6277 and AD-14419 to AD-14638. In further embodiments, the iRNA agents mediates the cleavage of a TGF-beta mRNA within the target sequence of an iRNA agent, comprises 15 or more contiguous nucleotides from an iRNA agent, or is an iRNA agent, selected from one of the following groups: the 20%-group, the 30%-group, the 40%-group, the 50%-group, the 60%-group, the 70%-group, the 80%-group, or the 90%-group, as defmed below. Said iRNA agent may be administered to a subject, wherein administration may comprise pulmonary administration. As a result of the inventive method, the level of TGF-beta protein and/or TGF-beta mRNA may be reduced by at least 20%.

In another aspect, the invention provides isolated iRNA agents, comprising an antisense strand consisting of 15 to 30 nucleotides and having at least 15 or more contiguous nucleotides complementary to a mammalian TGF-beta mRNA, and a sense strand consisting of 15 to 30 nucleotides and having at least 15 or more contiguous nucleotides complementary to said antisense strand. In one embodiment, said iRNA agent mediates the cleavage of a TGF-beta mRNA within the target sequence of an iRNA agent selected from one of the following groups: the group of AL-DP-6837 to AL-DP-6864 and AD-14419 to AD-14638, the 20%-group, the 30%-group, the 40%-group, the 50%-group, the 60%-group, the 70%-group, the 80%-group, or the 90%-group, as defined below. In a fuirther embodiment, said iRNA agent comprises 15 or more contiguous nucleotides from an iRNA agent selected from one of the following groups: the group of AL-DP-6837 to AL-DP-6864, AL-DP-6140 to AL-DP-6151, AL-DP-6262 to AL-DP-6277 and AD-14419 to AD-14638 the 20%-group, the 30%-group, the 40%-group, the 50%-group, the 60%-group, the 70%-group, the 80%-group, or the 90%-group, as defmed below. More specifically, said iRNA agent may be an iRNA agent selected from one of the following groups of: AL-DP-6837 to AL-DP-6864, AL-DP-6140 to AL-DP-6151, AL-DP-6262 to AL-DP-6277 and AD-14419 to AD-14638; the 20%-group, the 30%-group, the 40%-group, the 50%-group, the 60%-group, the 70%-group, the 80%-group, or the 90%-group, as defined below. The iRNA agent may further comprise a non-nucleotide moiety. Furthermore, the sense and/or antisense strand may be stabilized against nucleolytic degradation. The iRNA agent may further comprise at least one 3′-overhang, wherein said 3′-overhang comprises from I to 6 nucleotides. Also, the iRNA agent may comprise a phosphorothioate at the first intemucleotide linkage at the 5′ end of the antisense and/or sense sequence, and optionally a further phosphorothioate at the first intemucleotide linkage at the 3′ end of the antisense and/or sense sequence. The iRNA agent may comprise a 2′-modified nucleotide, preferably selected from the group consisting of: 2′-deoxy, 2′-deoxy-2′-fluoro, 2′-O-methyl, 2′-O-methoxyethyl (2′-O-MOE), 2′-O-aminopropyl (2′-O-AP), 2′-O-dimethylaminoethyl (2′-O-DMAOE), 2′-O-dimethylaminopropyl (2′-O-DMAP), 2′-O-dimethylaminoethyloxyethyl (2′-O-DMAEOE), and 2′-O-N-methylacetamido (2′-O-NMA).

In another aspect, the instant invention features a method of reducing the levels of a TGF-beta mRNA in a cell, or of TGF-beta protein secreted by a cell, comprising contacting the cell with an iRNA agent of the invention.

In yet another aspect, the instant invention provides a vector encoding an iRNA agent of the invention.

In yet another aspect, the instant invention provides a cell comprising an iRNA agent or a vector of the invention.

In yet another aspect, the a method of making an iRNA agent of the invention is provided, the method comprising the synthesis of the iRNA agent, wherein the sense and antisense strands comprise at least one modification that stabilizes the iRNA agent against nucleolytic degradation.

In yet another aspect, the instant invention provides a pharmaceutical composition comprising an iRNA agent of the invention and a pharmaceutically acceptable carrier.

In yet another aspect, the instant invention provides a method of treating a human diagnosed as having or at risk for developing a disease or disorder associated with undesired TGF-beta signaling, comprising administering to a subject in need of such treatment a therapeutically effective amount of an iRNA agent of the invention. In one embodiment, the human is diagnosed as having or at risk for having idiopathic pulmonary fibrosis, diabetic nephropathy or chronic liver disease.

Table 1 provides exemplary iRNA agents of the invention. TABLE 1 Oligonucleotide sequences of siRNAs specific for TGF-beta Position of target sequence in Duplex SEQ ID SEQ ID NM_000660.3 identifier sense strand sequence¹ NO: antisense strand sequence¹ NO: 1186-1208 AL-DP-6837 ggucacccgcgugcuaaugTT 1 cauuagcacgcgggugaccTT 2 1186-1208 AL-DP-6140 ggumcmacmcmcmgcmgumgcmumaaumgTT 3 cmauumagcmacgcgggugaccTT 4 1184-1206 AL-DP-6838 gaggucacccgcgugcuaaTT 5 uuagcacgcgggugaccucTT 6 1184-1206 AL-DP-6141 gaggumcmacmcmcmgcmgumgcmumaaTT 7 uumagcmacgcgggugaccucTT 8 1112-1134 AL-DP-6839 agcacccgcgaccggguggTT 9 ccacccggucgcgggugcuTT 10 1112-1134 AL-DP-6142 agcmacmcmcmgcmgacmcmgggumggTT 11 ccmacccggucgcgggugcuTT 12 1797-1819 AL-DP-6840 uccacgagcccaagggcuaTT 13 uagcccuugggcucguggaTT 14 1797-1819 AL-DP-6143 umcmcmacmgagcmcmcmaagggcmumaTT 15 umagcccuugggcucguggaTT 16 444-466 AL-DP-6841 auuccggaccagcccucggTT 17 ccgagggcugguccggaauTT 18 444-466 AL-DP-6144 aumumcmcmggacmcmagcmcmcmumcmggTT 19 ccgagggcugguccggaauTT 20 1185-1207 AL-DP-6842 aggucacccgcgugcuaauTT 21 auuagcacgcgggugaccuTT 22 1185-1207 AL-DP-6145 aggumcmacmcmcmgcmgumgcmumaaumTT 23 auumagcmacgcgggugaccuTT 24 445-467 AL-DP-6843 uuccggaccagcccucgggTT 25 cccgagggcugguccggaaTT 26 445-467 AL-DP-6146 umumcmcmggacmcmagcmcmcmumcmgggTT 27 cccgagggcugguccggaaTT 28 1104-1126 AL-DP-6844 uguacaacagcacccgcgaTT 29 ucgcgggugcuguuguacaTT 30 1104-1126 AL-DP-6147 umgumacmaacmagcmacmcmcmgcmgaTT 31 ucgcgggugcuguugumacmaTT 32 1189-1211 AL-DP-6845 cacccgcgugcuaauggugTT 33 caccauuagcacgcgggugTT 34 1189-1211 AL-DP-6148 cmacmcmcmgcmgumgcmumaaumggumgTT 35 cmaccmauumagcmacgcgggugTT 36 446-468 AL-DP-6846 uccggaccagcccucgggaTT 37 ucccgagggcugguccggaTT 38 446-468 AL-DP-6149 umcmcmggacmcmagcmcmcmumcmgggaTT 39 ucccgagggcugguccggaTT 40 1787-1809 AL-DP-6847 uggaaguggauccacgagcTT 41 gcucguggauccacuuccaTT 42 1787-1809 AL-DP-6150 umggaagumggaumcmcmacmgagcmTT 43 gcucguggauccmacuuccmaTT 44 1806-1828 AL-DP-6848 ccaagggcuaccaugccaaTT 45 uuggcaugguagcccuuggTT 46 1806-1828 AL-DP-6151 cmcmaagggcmumacmcmaumgcmcmaaTT 47 uuggcmauggumagcccuuggTT 48 1187-1209 AL-DP-6849 gucacccgcgugcuaauggTT 49 ccauuagcacgcgggugacTT 50 1187-1209 AL-DP-6262 gumcmacmcmcmgcmgumgcmumaaumggTT 51 ccmauumagcmacgcgggugacTT 52 1106-1128 AL-DP-6850 uacaacagcacccgcgaccTT 53 ggucgcgggugcuguuguaTT 54 1106-1128 AL-DP-6263 umacmaacmagcmacmcmcmgcmgacmcmTT 55 ggucgcgggugcuguugumaTT 56 1804-1826 AL-DP-6851 gcccaagggcuaccaugccTT 57 ggcaugguagcccuugggcTT 58 1804-1826 AL-DP-6264 gcmcmcmaagggcmumacmcmaumgcmcmTT 59 ggcmauggumagcccuugggcTT 60 1790-1812 AL-DP-6852 aaguggauccacgagcccaTT 61 ugggcucguggauccacuuTT 62 1790-1812 AL-DP-6265 aagumggaumcmcmacmgagcmcmcmaTT 63 ugggcucguggauccmacuuTT 64 239-261 AL-DP-6853 gggaggagggacgagcuggTT 65 ccagcucgucccuccucccTT 66 239-261 AL-DP-6266 gggaggagggacmgagcmumggTT 67 ccmagcucgucccuccucccTT 68 1107-1129 AL-DP-6854 acaacagcacccgcgaccgTT 69 cggucgcgggugcuguuguTT 70 1107-1129 AL-DP-6267 acmaacmagcmacmcmcmgcmgacmcmgTT 71 cggucgcgggugcuguuguTT 72 1807-1829 AL-DP-6855 caagggcuaccaugccaacTT 73 guuggcaugguagcccuugTT 74 1807-1829 AL-DP-6268 cmaagggcmumacmcmaumgcmcmaacmTT 75 guuggcmauggumagcccuugTT 76 447-469 AL-DP-6856 ccggaccagcccucgggagTT 77 cucccgagggcugguccggTT 78 447-469 AL-DP-6269 cmcmggacmcmagcmcmcmumcmgggagTT 79 cucccgagggcugguccggTT 80 1711-1733 AL-DP-6857 caacuauugcuucagcuccTT 81 ggagcugaagcaauaguugTT 82 1711-1733 AL-DP-6270 cmaacmumaumumgcmumummagcmumcmcmTT 83 ggagcugaagcmaaumaguugTT 84 1748-1770 AL-DP-6858 gugcggcagcuguacauugTT 85 caauguacagcugccgcacTT 86 1748-1770 AL-DP-6271 gumgcmggcmagcmumgumacmaumumgTT 87 cmaaugumacmagcugccgcmacTT 88 1788-1810 AL-DP-6859 ggaaguggauccacgagccTT 89 ggcucguggauccacuuccTT 90 1788-1810 AL-DP-6272 ggaagumggaumcmcmacmgagcmcmTT 91 ggcucguggauccmacuuccTT 92 1789-1811 AL-DP-6860 gaaguggauccacgagcccTT 93 gggcucguggauccacuucTT 94 1789-1811 AL-DP-6273 gaagumggaumcmcmacmgagcmcmcmTT 95 gggcucguggauccmacuucTT 96 1798-1820 AL-DP-6861 ccacgagcccaagggcuacTT 97 guagcccuugggcucguggTT 98 1798-1820 AL-DP-6274 cmcmacmgagcmcmcmaagggcmumacmTT 99 gumagcccuugggcucguggTT 100 1802-1824 AL-DP-6862 gagcccaagggcuaccaugTT 101 caugguagcccuugggcucTT 102 1802-1824 AL-DP-6275 gagcmcmcmaagggcmumacmcmaumgTT 103 cmauggumagcccuugggcucTT 104 1803-1825 AL-DP-6863 agcccaagggcuaccaugcTT 105 gcaugguagcccuugggcuTT 106 1803-1825 AL-DP-6276 agcmcmcmaagggcmumacmcmaumgcmTT 107 gcmauggumagcccuugggcuTT 108 1926-1948 AL-DP-6864 cgugcugcgugccgcaggcTT 109 gccugcggcacgcagcacgTT 110 1926-1948 AL-DP-6277 cmgumgcmumgcmgumgcmcmgcmaggcmTT 111 gccugcggcmacgcmagcmacgTT 112 ¹a, g, c, u: ribonucleotide 5′-monophosphates (except where in 5′-most position, see below); cm: 2′-O-methyl-cytidine-5′-monophosphate (except where in 5′-most position, see below); um: 2′-O-methyl-uridine-5′-monophosphate (except where in 5′-most position, see below); T: deoxythymidine 5′-monophosphate; T: deoxythymidine 5′-monothiophosphate; all sequences given 5′ → 3′; due to synthesis procedures, the 5′-most nucleic acid is a # nucleoside, i.e. does not bear a 5′-monophosate group

The iRNA agents of the invention can either contain only naturally occurring ribonucleotide subunits, or can be synthesized so as to contain one or more modifications to the base, the sugar or the phosphate group of one or more of the ribonucleotide 5′-monophosphate subunits that is included in the agent. The iRNA agent can be further modified so as to be attached to a ligand that is selected to improve stability, distribution or cellular uptake of the agent, e.g. cholesterol. The iRNA agents can further be in isolated form or can be part of a pharmaceutical composition used for the methods described herein, particularly as a pharmaceutical composition formulated for delivery to the lung or formulated for parenteral administration. The pharmaceutical compositions can contain one or more iRNA agents, and in some embodiments, will contain two or more iRNA agents, each one directed to a different segment of a TGF-beta gene or a different TGF-beta gene.

In a preferred embodiment, an iRNA agent of the invention reduces the level of TGF-beta protein secreted by, and/or TGF-beta mRNA found inside, a cell by at least 20% or more. Thus, the iRNA agent may preferably be chosen from the group of AD-14501, AD-14503, AD-14507, AD-14554, AD-14594, AD-14597, AD-14633, AL-DP-6858, AL-DP-6857, AL-DP-6859, AL-DP-6848, AL-DP-6862, AD-14419, AD-14420, AD-14421, AD-14422, AD-14423, AD-14428, AD-14430, AD-14434, AD-14438, AD-14449, AD-14453, AD-14459, AD-14460, AD-1 4464, AD-1 4469, AD-1 4470, AD-1 4473, AD-1 4474, AD-1 4476, AD-14486, AD-14490, AD-14495, AD-14496, AD-14497, AD-14509, AD-14515, AD-14522, AD-14526, AD-14540, AD-14552, AD-14555, AD-14557, AD-14565, AD-14567, AD-14568, AD-14582, AD-14588, AD-14590, AD-14592, AD-14598, AD-14600, AD-14601, AD-14603, AD-14604, AD-14608, AD-14610, AD-14612, AD-14614, AD-1 4622, AD-14634, AD-14635, AL-DP-6845, AL-DP-6852, AL-DP-6838, AL-DP-6855, AL-DP-6264, AL-DP-6851, AL-DP-6842, AL-DP-6837, AD-14425, AD-14426, AD-14427, AD-14429, AD-14431, AD-14436, AD-14437, AD-14441, AD-14448, AD-14458, AD-14463, AD-14467, AD-14477, AD-14482, AD-14483, AD-14491, AD-14502, AD-14505, AD-14508, AD-14512, AD-14513, AD-14519, AD-14524, AD-14537, AD-14546, AD-14548, AD-14549, AD-14559, AD-14563, AD-14564, AD-14569, AD-14578, AD-14579, AD-14587, AD-14595, AD-14599, AD-14607, AD-14609, AD-14629, AD-14631, AD-14637, AL-DP-6840, AL-DP-6860, AL-DP-6861, AL-DP-6849, AL-DP-6272, AL-DP-6271, AL-DP-6847, AL-DP-6863, AD-14447, AD-14451, AD-14471, AD-14484, AD-14487, AD-14498, AD-14523, AD-14527, AD-14529, AD-14539, AD-14541, AD-14558, AD-14561, AD-14573, AD-14589, AD-14596, AD-14605, AD-14615, AD-14626, AD-14630, AL-DP-6846, AL-DP-6853, AL-DP-6856, AL-DP-6864, AL-DP-6844, AL-DP-6143, AD-14432, AD-14480, AD-14485, AD-14488, AD-14499, AD-14504, AD-14516, AD-14518, AD-14520, AD-14547, AD-14572, AD-14577, AD-14580, AD-14583, AD-14584, AD-14618, AD-14621, AD-14625, AL-DP-6276, AD-14435, AD-14445, AD-14450, AD-14456, AD-14466, AD-14475, AD-14489, AD-14492, AD-14511, AD-14535, AD-14536, AD-14538, AD-14553, AD-14560, AD-14562, AD-14576, AD-14581, AD-14586, AD-14627, AL-DP-6150 AL-DP-6850, AD-14433, AD-14472, AD-14478, AD-14493, AD-14510, AD-14544, AD-14566, AD-14570, AD-14575, AD-14593, AD-14613, AL-DP-6269, AL-DP-6270, AL-DP-6147, AL-DP-6262, AL-DP-6841, AL-DP-6274, AL-DP-6843, AL-DP-6145, AD-14424, AD-14442, AD-14444, AD-14446, AD-14454, AD-14525, AD-14543, AD-14571, AD-14606, AD-14611, AD-14616, AD-14617, AD-14619, and AD-14638 (the “20% group”).

More preferably, an iRNA agent of the invention reduces the level of TGF-beta protein secreted by, and/or TGF-beta mRNA found inside, a cell by at least 30% or more. Thus, the iRNA agent may preferably be chosen from the group of AD-14501, AD-14503, AD-14507, AD-14554, AD-14594, AD-14597, AD-14633, AL-DP-6858, AL-DP-6857, AL-DP-6859, AL-DP-6848, AL-DP-6862, AD-14419, AD-14420, AD-14421, AD-14422, AD-14423, AD-1 4428, AD-14430, AD-14434, AD-14438, AD-14449, AD-14453, AD-14459, AD-14460, AD-1 4464, AD-14469, AD-1 4470, AD-1 4473, AD-14474, AD-1 4476, AD-1 4486, AD-14490, AD-14495, AD-14496, AD-14497, AD-14509, AD-14515, AD-1 4522, AD-14526, AD-14540, AD-14552, AD-14555, AD-14557, AD-14565, AD-14567, AD-14568, AD-14582, AD-14588, AD-14590, AD-14592, AD-14598, AD-14600, AD-14601, AD-14603, AD-14604, AD-14608, AD-14610, AD-14612, AD-14614, AD-14622, AD-14634, AD-14635, AL-DP-6845, AL-DP-6852, AL-DP-6838, AL-DP-6855, AL-DP-6264, AL-DP-6851, AL-DP-6842, AL-DP-6837, AD-14425, AD-14426, AD-14427, AD-14429, AD-14431, AD-14436, AD-14437, AD-14441, AD-14448, AD-14458, AD-14463, AD-14467, AD-14477, AD-14482, AD-14483, AD-14491, AD-14502, AD-14505, AD-14508, AD-14512, AD-14513, AD-14519, AD-14524, AD-14537, AD-14546, AD-14548, AD-14549, AD-14559, AD-14563, AD-14564, AD-14569, AD-14578, AD-14579, AD-14587, AD-14595, AD-14599, AD-14607, AD-14609, AD-14629, AD-14631, AD-14637, AL-DP-6840, AL-DP-6860, AL-DP-6861, AL-DP-6849, AL-DP-6272, AL-DP-6271, AL-DP-6847, AL-DP-6863, AD-14447, AD-14451, AD-14471, AD-14484, AD-14487, AD-14498, AD-14523, AD-14527, AD-14529, AD-14539, AD-14541, AD-14558, AD-14561, AD-14573, AD-14589, AD-14596, AD-14605, AD-14615, AD-14626, AD-14630, AL-DP-6846, AL-DP-6853, AL-DP-6856, AL-DP-6864, AL-DP-6844, AL-DP-6143, AD-14432, AD-14480, AD-14485, AD-14488, AD-14499, AD-14504, AD-14516, AD-14518, AD-14520, AD-14547, AD-14572, AD-14577, AD-14580, AD-14583, AD-14584, AD-14618, AD-14621, AD-14625, AL-DP-6276, AD-14435, AD-14445, AD-14450, AD-14456, AD-14466, AD-14475, AD-14489, AD-14492, AD-14511, AD-14535, AD-14536, AD-14538, AD-14553, AD-14560, AD-14562, AD-14576, AD-14581, AD-14586, AD-14627, AL-DP-6150 AL-DP-6850, AD-14433, AD-14472, AD-14478, AD-14493, AD-14510, AD-14544, AD-14566, AD-14570, AD-14575, AD-14593, and AD-14613 (the “30% group”).

More preferably, an iRNA agent of the invention reduces the level of TGF-beta protein secreted by, and/or TGF-beta mRNA found inside, a cell by at least 40% or more. Thus, the iRNA agent may preferably be chosen from the group of AD-14501, AD-14503, AD-14507, AD-14554, AD-14594, AD-14597, AD-14633, AL-DP-6858, AL-DP-6857, AL-DP-6859, AL-DP-6848, AL-DP-6862, AD-14419, AD-14420, AD-14421, AD-14422, AD-14423, AD-14428, AD-14430, AD-14434, AD-14438, AD-14449, AD-14453, AD-14459, AD-14460, AD-14464, AD-1 4469, AD-14470, AD-14473, AD-1 4474, AD-14476, AD-1 4486, AD-14490, AD-14495, AD-14496, AD-14497, AD-14509, AD-14515, AD-14522, AD-14526, AD-14540, AD-14552, AD-14555, AD-14557, AD-14565, AD-14567, AD-14568, AD-14582, AD-14588, AD-14590, AD-14592, AD-14598, AD-14600, AD-14601, AD-14603, AD-14604, AD-14608, AD-14610, AD-14612, AD-14614, AD-14622, AD-14634, AD-14635, AL-DP-6845, AL-DP-6852, AL-DP-6838, AL-DP-6855, AL-DP-6264, AL-DP-6851, AL-DP-6842, AL-DP-6837, AD-14425, AD-14426, AD-14427, AD-14429, AD-14431, AD-14436, AD-14437, AD-14441, AD-14448, AD-14458, AD-14463, AD-14467, AD-14477, AD-14482, AD-14483, AD-14491, AD-14502, AD-14505, AD-14508, AD-14512, AD-14513, AD-14519, AD-14524, AD-14537, AD-14546, AD-14548, AD-14549, AD-14559, AD-14563, AD-14564, AD-14569, AD-14578, AD-14579, AD-14587, AD-14595, AD-14599, AD-14607, AD-14609, AD-14629, AD-14631, AD-14637, AL-DP-6840, AL-DP-6860, AL-DP-6861, AL-DP-6849, AL-DP-6272, AL-DP-6271, AL-DP-6847, AL-DP-6863, AD-14447, AD-14451, AD-14471, AD-14484, AD-14487, AD-14498, AD-14523, AD-14527, AD-14529, AD-14539, AD-14541, AD-14558, AD-14561, AD-14573, AD-14589, AD-14596, AD-14605, AD-14615, AD-14626, AD-14630, AL-DP-6846, AL-DP-6853, AL-DP-6856, AL-DP-6864, AL-DP-6844, AL-DP-6143, AD-14432, AD-14480, AD-14485, AD-14488, AD-14499, AD-14504, AD-14516, AD-14518, AD-14520, AD-14547, AD-14572, AD-14577, AD-14580, AD-14583, AD-14584, AD-14618, AD-14621, AD-14625, AL-DP-6276, AD-14435, AD-14445, AD-14450, AD-14456, AD-14466, AD-14475, AD-14489, AD-14492, AD-14511, AD-14535, AD-14536, AD-14538, AD-14553, AD-14560, AD-14562, AD-14576, AD-14581, AD-14586, and AD-14627 (the “40% group”).

More preferably, an iRNA agent of the invention reduces the level of TGF-beta protein secreted by, and/or TGF-beta mRNA found inside, a cell by at least 50% or more. Thus, the iRNA agent may preferably be chosen from the group of AD-14501, AD-14503, AD-14507, AD-14554, AD-14594, AD-14597, AD-14633, AL-DP-6858, AL-DP-6857, AL-DP-6859, AL-DP-6848, AL-DP-6862, AD-14419, AD-14420, AD-14421, AD-14422, AD-14423, AD-14428, AD-14430, AD-14434, AD-14438, AD-14449, AD-14453, AD-14459, AD-14460, AD-14464, AD-14469, AD-14470, AD-14473, AD-14474, AD-14476, AD-14486, AD-14490, AD-14495, AD-14496, AD-14497, AD-14509, AD-14515, AD-14522, AD-14526, AD-14540, AD-14552, AD-14555, AD-14557, AD-14565, AD-14567, AD-14568, AD-14582, AD-14588, AD-14590, AD-14592, AD-14598, AD-14600, AD-14601, AD-14603, AD-14604, AD-14608, AD-14610, AD-14612, AD-14614, AD-14622, AD-14634, AD-14635, AL-DP-6845, AL-DP-6852, AL-DP-6838, AL-DP-6855, AL-DP-6264, AL-DP-6851, AL-DP-6842, AL-DP-6837, AD-14425, AD-14426, AD-14427, AD-14429, AD-14431, AD-14436, AD-14437, AD-14441, AD-14448, AD-14458, AD-14463, AD-14467, AD-14477, AD-14482, AD-14483, AD-14491, AD-14502, AD-14505, AD-14508, AD-14512, AD-14513, AD-14519, AD-14524, AD-14537, AD-14546, AD-14548, AD-14549, AD-14559, AD-14563, AD-14564, AD-14569, AD-14578, AD-14579, AD-14587, AD-14595, AD-14599, AD-14607, AD-14609, AD-14629, AD-14631, AD-14637, AL-DP-6840, AL-DP-6860, AL-DP-6861, AL-DP-6849, AL-DP-6272, AL-DP-6271, AL-DP-6847, AL-DP-6863, AD-14447, AD-14451, AD-14471, AD-14484, AD-14487, AD-14498, AD-14523, AD-14527, AD-14529, AD-14539, AD-14541, AD-14558, AD-14561, AD-14573, AD-14589, AD-14596, AD-14605, AD-14615, AD-14626, AD-14630, AL-DP-6846, AL-DP-6853, AL-DP-6856, AL-DP-6864, AL-DP-6844, AL-DP-6143, AD-14432, AD-14480, AD-14485, AD-14488, AD-14499, AD-14504, AD-14516, AD-14518, AD-14520, AD-14547, AD-14572, AD-14577, AD-14580, AD-14583, AD-14584, AD-14618, AD-14621, and AD-14625 (the “50% group”).

Yet more preferably, an iRNA agent of the invention reduces the level of TGF-beta protein secreted by, and/or TGF-beta mRNA found inside, a cell by at least 60% or more. Thus, the iRNA agent may preferably be chosen from the group of AD-14501, AD-14503, AD-14507, AD-14554, AD-14594, AD-14597, AD-14633, AL-DP-6858, AL-DP-6857, AL-DP-6859, AL-DP-6848, AL-DP-6862, AD-14419, AD-14420, AD-14421, AD-1 4422, AD-14423, AD-14428, AD-14430, AD-14434, AD-14438, AD-14449, AD-14453, AD-14459, AD-14460, AD-14464, AD-1 4469, AD-14470, AD-14473, AD-1 4474, AD-1 4476, AD-1 4486, AD-14490, AD-14495, AD-14496, AD-14497, AD-14509, AD-14515, AD-14522, AD-14526, AD-14540, AD-14552, AD-14555, AD-14557, AD-14565, AD-14567, AD-14568, AD-14582, AD-14588, AD-14590, AD-14592, AD-14598, AD-14600, AD-14601, AD-14603, AD-14604, AD-14608, AD-14610, AD-14612, AD-14614, AD-1 4622, AD-1 4634, AD-14635, AL-DP-6845, AL-DP-6852, AL-DP-6838, AL-DP-6855, AL-DP-6264, AL-DP-6851, AL-DP-6842, AL-DP-6837, AD-14425, AD-14426, AD-14427, AD-14429, AD-14431, AD-14436, AD-14437, AD-14441, AD-14448, AD-14458, AD-14463, AD-14467, AD-14477, AD-14482, AD-14483, AD-14491, AD-14502, AD-14505, AD-14508, AD-14512, AD-14513, AD-14519, AD-14524, AD-14537, AD-14546, AD-14548, AD-14549, AD-14559, AD-14563, AD-14564, AD-14569, AD-14578, AD-14579, AD-14587, AD-14595, AD-14599, AD-14607, AD-14609, AD-14629, AD-14631, AD-14637, AL-DP-6840, AL-DP-6860, AL-DP-6861, AL-DP-6849, AL-DP-6272, AL-DP-6271, AL-DP-6847, AL-DP-6863, AD-14447, AD-14451, AD-14471, AD-14484, AD-14487, AD-14498, AD-14523, AD-1.4527, AD-14529, AD-14539, AD-14541, AD-14558, AD-14561, AD-14573, AD-14589, AD-14596, AD-14605, AD-14615, AD-14626, and AD-14630 (the “60% group”).

Yet more preferably, an iRNA agent of the invention reduces the level of TGF-beta protein secreted by, and/or TGF-beta mRNA found inside, a cell by at least 70% or more. Thus, the iRNA agent may preferably be chosen from the group of AD-14501, AD-14503, AD-14507, AD-14554, AD-14594, AD-14597, AD-14633, AL-DP-6858, AL-DP-6857, AL-DP-6859, AL-DP-6848, AL-DP-6862, AD-14419, AD-14420, AD-14421, AD-14422, AD-14423, AD-14428, AD-14430, AD-14434, AD-14438, AD-14449, AD-14453, AD-14459, AD-14460, AD-14464, AD-14469, AD-14470, AD-14473, AD-14474, AD-14476, AD-14486, AD-14490, AD-14495, AD-14496, AD-14497, AD-14509, AD-14515, AD-14522, AD-14526, AD-14540, AD-14552, AD-14555, AD-14557, AD-14565, AD-14567, AD-14568, AD-14582, AD-14588, AD-14590, AD-14592, AD-14598, AD-14600, AD-14601, AD-14603, AD-14604, AD-14608, AD-14610, AD-14612, AD-14614, AD-14622, AD-14634, AD-14635, AL-DP-6845, AL-DP-6852, AL-DP-6838, AL-DP-6855, AL-DP-6264, AL-DP-6851, AL-DP-6842, AL-DP-6837, AD-14425, AD-14426, AD-14427, AD-14429, AD-14431, AD-14436, AD-14437, AD-14441, AD-14448, AD-14458, AD-14463, AD-14467, AD-14477, AD-14482, AD-14483, AD-14491, AD-14502, AD-14505, AD-14508, AD-14512, AD-14513, AD-14519, AD-14524, AD-14537, AD-14546, AD-14548, AD-14549, AD-14559, AD-14563, AD-14564, AD-14569, AD-14578, AD-14579, AD-14587, AD-14595, AD-14599, AD-14607,

AD-14609, AD-14629, AD-14631, and AD-14637 (the “70% group”).

Yet more preferably, an iRNA agent of the invention reduces the level of TGF-beta protein secreted by, and/or TGF-beta mRNA found inside, a cell by at least 80% or more. Thus, the iRNA agent may preferably be chosen from the group of AD-14501, AD-1 4503, AD-14507, AD-14554, AD-14594, AD-14597, AD-14633, AL-DP-6858, AL-DP-6857, AL-DP-6859, AL-DP-6848, AL-DP-6862, AD-14419, AD-14420, AD-14421, AD-14422, AD-14423, AD-14428, AD-14430, AD-14434, AD-14438, AD-14449, AD-14453, AD-14459, AD-14460, AD-1 4464, AD-1 4469, AD-1 4470, AD-1 4473, AD-1 4474, AD-14476, AD-1 4486, AD-14490, AD-14495, AD-14496, AD-14497, AD-14509, AD-14515, AD-14522, AD-14526, AD-14540, AD-14552, AD-14555, AD-14557, AD-14565, AD-14567, AD-14568, AD-14582, AD-14588, AD-14590, AD-14592, AD-14598, AD-14600, AD-14601, AD-14603, AD-14604, AD-14608, AD-14610, AD-14612, AD-14614, AD-1 4622, AD-1 4634, and AD-14635 (the “80% group”).

Yet more preferably, an iRNA agent of the invention reduces the level of TGF-beta protein secreted by, and/or TGF-beta mRNA found inside, a cell by at least 90% or more. Thus, the iRNA agent may preferably be chosen from the group of AD-14501, AD-14503, AD-14507, AD-14554, AD-14594, AD-14597, and AD-14633 (the “90% group”).

The present invention provides methods for reducing the level of TGF-beta protein and TGF-beta mRNA in a cell. Such methods optionally comprise the step of administering one of the iRNA agents of the present invention to a subject as further described below. The present methods utilize the cellular mechanisms involved in RNA interference to selectively degrade the TGF-beta mRNA in a cell and are comprised of the step of contacting a cell with one of the TGF-beta iRNA agents of the present invention. Such methods can be performed directly on a cell or can be performed on a mammalian subject by administering to a subject one of the iRNA agents/pharmaceutical compositions of the present invention. Reduction of TGF-beta mRNA in a cell results in a reduction in the amount of TGF-beta protein produced, and in an organism (as shown in the Examples).

The methods and compositions of the invention, e.g., the methods and iRNA agent compositions can be used with any dosage and/or formulation described herein, as well as with any route of administration described herein.

In another aspect, the invention features a method for treating or preventing a disease or condition associated with undesired TGF-beta signaling in a subject. The method can include administering to the subject a composition of the invention under conditions suitable for the treatment or prevention of the disease or condition associated with undesired TGF-beta signaling in the subject, alone or in conjunction with one or more other therapeutic compounds.

In one embodiment, the iRNA agent is administered at or near the site of undesired TGF-beta signaling, e.g., direct injection at the site, or by a catheter or other placement device (e.g., an implant including a porous, non-porous, or gelatinous material). In another embodiment the iRNA agent is administered via pulmonary delivery, e.g. by inhalation, which may be nasal and/or oral.

In one embodiment, an iRNA agent is administered repeatedly. Administration of an iRNA agent can be carried out over a range of time periods. It can be administered hourly, daily, once every few days, weekly, or monthly. The timing of administration can vary from patient to patient, depending upon such factors as the severity of a patient's symptoms. For example, an effective dose of an iRNA agent can be administered to a patient once a month for an indefinite period of time, or until the patient no longer requires therapy. In addition, sustained release compositions containing an iRNA agent can be used to maintain a relatively constant dosage in the area of the target TGF-beta nucleotide sequences.

In another embodiment, an iRNA agent is delivered at a dosage on the order of about 0.00001 mg to about 3 mg per kg body weight of the subject to be treated, or preferably about 0.0001-0.001 mg per kg body weight, about 0.03- 3.0 mg per kg body weight, about 0.1-3.0 mg per kg body weight or about 0.3-3.0 mg per kg body weight.

In another embodiment, an iRNA agent is administered prophylactically such as to prevent or slow the onset of a disease or disorder or condition associated with undesired TGF-beta signaling. For example, an iRNA can be administered to a patient who is susceptible to or otherwise at risk for such a disease or disorder.

In another aspect, a method of inhibiting TGF-beta expression is provided. One such method includes administering an effective amount of an iRNA agent including sense and antisense sequences capable of forming an RNA duplex. The sense sequence of the iRNA agent can include a nucleotide sequence substantially identical to a target sequence of about 19 to 23 nucleotides of TGF-beta mRNA, and the antisense sequence can include a nucleotide sequence complementary to a target sequence of about 19-23 nucleotides of TGF-beta mRNA.

In one aspect, methods of treating any disease or disorder associated with undesired TGF-beta signaling are provided.

In another aspect, a method of treating idiopathic pulmonary fibrosis is provided. One such method includes administering a therapeutically effective amount of an iRNA agent that includes sense and antisense sequences capable of forming an RNA duplex. The sense sequence can include a nucleotide sequence substantially identical to a target sequence of about 19 to 23 nucleotides of TGF-beta mRNA. The antisense sequence can include a nucleotide sequence complementary to a target sequence of about 19 to 23 nucleotides of TGF-beta mRNA.

In one embodiment, a human has been diagnosed with a disease or disorder associated with undesired TGF-beta signaling. In one embodiment, said disease or disorder is Interstitial Lung Disease (ILD). In a preferred embodiment, the human has been diagnosed with one of: Idiopathic pulmonary fibrosis, Hypersensitivity pneumonitis, Sarcoidosis, Eosinophilic granuloma, Wegener's granulomatosis, Idiopathic pulmonary hemosiderosis, and Bronchiolitis obliterans. In a particularly preferred embodiment, the human has been diagnosed with idiopathic pulmonary fibrosis.

In another aspect, the invention features a kit containing an iRNA agent of the invention. The iRNA agent of the kit can be chemically modified and can be useful for modulating the expression of a TGF-beta target gene in a cell, tissue or organism. In one embodiment, the kit contains more than one iRNA agent of the invention.

The details of one or more embodiments of the invention are set forth in the description below. Other features, objects, and advantages of the invention will be apparent from this description and from the claims. This application incorporates all cited references, patents, and patent applications by references in their entirety for all purposes.

DETAILED DESCRIPTION

For ease of exposition the term “nucleotide” or “ribonucleotide” is sometimes used herein in reference to one or more monomeric subunits of an RNA agent. It will be understood that the usage of the term “ribonucleotide” or “nucleotide” herein can, in the case of a modified RNA or nucleotide surrogate, also refer to a modified nucleotide, or surrogate replacement moiety, as further described below, at one or more positions.

An “RNA agent” as used herein, is an unmodified RNA, modified RNA, or nucleoside surrogate, all of which are described herein or are well known in the RNA synthetic art. While numerous modified RNAs and nucleoside surrogates are described, preferred examples include those which have greater resistance to nuclease degradation than do unmodified RNAs. Examples include those that have a 2′ sugar modification, a modification in a single strand overhang, such as a 3′ single strand overhang, or, particularly if single stranded, a 5′-modification which includes one or more phosphate groups or one or more analogs of a phosphate group.

An “iRNA agent” (abbreviation for “interfering RNA agent”) as used herein, is an RNA agent, which can down-regulate the expression of a target gene, e.g., a TGF-beta gene, and preferably a human TGF-beta gene. While not wishing to be bound by theory, an iRNA agent may act by one or more of a number of mechanisms, including post-transcriptional cleavage of a target mRNA sometimes referred to in the art as RNA interference or RNAi, or pre-transcriptional or pre-translational mechanisms. An iRNA agent can be a double stranded (ds) iRNA agent.

A “ds iRNA agent” (abbreviation for “double stranded iRNA agent”), as used herein, is an iRNA agent which includes more than one, and preferably two, strands in which interchain hybridization can form a region of duplex structure. A “strand” herein refers to a contiguous sequence of nucleotides (including non-naturally occurring or modified nucleotides). The two or more strands may be, or each form a part of, separate molecules, or they may be covalently interconnected, e.g. by a linker, e.g. a polyethylene glycol linker, to form but one molecule. At least one strand can include a region which is sufficiently complementary to a target RNA. Such strand is termed the “antisense strand”. A second strand comprised in the dsRNA agent that comprises a region complementary to the antisense strand is termed the “sense strand”. However, a ds iRNA agent can also be formed from a single RNA molecule which is, at least partly; self-complementary, forming, e.g., a hairpin or panhandle structure, including a duplex region. In such case, the term “strand” refers to one of the regions of the RNA molecule that is complementary to another region of the same RNA molecule.

Although, in mammalian cells, long ds iRNA agents can induce the interferon response which is frequently deleterious, short ds iRNA agents do not trigger the interferon response, at least not to an extent that is deleterious to the cell and/or host. The iRNA agents of the present invention include molecules which are sufficiently short that they do not trigger a deleterious interferon response in mammalian cells. Thus, the administration of a composition of an iRNA agent (e.g., formulated as described herein) to a mammalian cell can be used to silence expression of an TGF-beta gene while circumventing a deleterious interferon response. Molecules that are short enough that they do not trigger a deleterious interferon response are termed siRNA agents or siRNAs herein. “siRNA agent” or “siRNA” as used herein, refers to an iRNA agent, e.g., a ds iRNA agent, that is sufficiently short that it does not induce a deleterious interferon response in a human cell, e.g., it has a duplexed region of less than 60 but preferably less than 50, 40, or 30 nucleotide pairs.

The isolated iRNA agents described herein, including ds iRNA agents and siRNA agents, can mediate silencing of a gene, e.g., by RNA degradation. For convenience, such RNA is also referred to herein as the RNA to be silenced, or target RNA. Such a gene is also referred to as a target gene. Preferably, the RNA to be silenced is a gene product of a TGF-beta gene.

As used herein, the phrases “mediate RNAi”, “silence a TGF-beta gene”, “reducing the level of TGF-beta mRNA” and/or “reducing the level of TGF-beta protein” all refer to the at least partial suppression of the expression of the TGF-beta gene, as manifested, e.g., by a reduction of the amount of mRNA transcribed from the TGF-beta gene which may be isolated from a first cell or group of cells in which the TGF-beta gene is transcribed and which has or have been treated such that the expression of the TGF-beta gene is inhibited, as compared to a second cell or group of cells substantially identical to the first cell or group of cells but which has or have not been so treated (control cells). Alternatively, the degree of inhibition may be given in terms of a reduction of a parameter that is functionally linked to TGF-beta gene transcription, e.g. the amount of protein encoded by the TGF-beta gene which is secreted by a cell, or the number of cells displaying a certain phenotype associated with TGF-beta signalling. The degree of inhibition is usually expressed in terms of ${\frac{\left( {{mRNA}\quad{in}\quad{control}\quad{cells}} \right) - \left( {{mRNA}\quad{in}\quad{treated}\quad{cells}} \right)}{\left( {{mRNA}\quad{in}\quad{control}\quad{cells}} \right)} \cdot 100}\%$

(“mRNA” may be replaced by another parameter used to assess TGF-beta gene expression, where applicable)

For example, in certain instances, expression of the TGF-beta gene is suppressed by at least about 20%, 25%, 35%, or 50% by administration of the double-stranded oligonucleotide of the invention. In a preferred embodiment, the TGF-beta gene is suppressed by at least about 60%, 70%, or 80% by administration of the double-stranded oligonucleotide of the invention. In a more preferred embodiment, the TGF-beta gene is suppressed by at least about 85%, 90%, or 95% by administration of the double-stranded oligonucleotide of the invention. In a most preferred embodiment, the TGF-beta gene is suppressed by at least about 98%, 99% or more by administration of the double-stranded oligonucleotide of the invention.

In principle, TGF-beta gene silencing may be determined in any cell expressing the target, either constitutively or by genomic engineering, and by any appropriate assay. However, when a reference is needed in order to determine whether a given siRNA inhibits the expression of the TGF-beta gene by a certain degree and therefore is encompassed by the instant invention, the assay provided in the Examples below shall serve as such reference.

As used herein, and unless otherwise indicated, the term “complementary,” when used to describe a first nucleotide sequence in relation to a second nucleotide sequence, refers to the ability of an oligonucleotide or polynucleotide comprising the first nucleotide sequence to hybridize and form a duplex structure under certain conditions with an oligonucleotide or polynucleotide comprising the second nucleotide sequence, as will be understood by the skilled person. Such conditions can, for example, be stringent conditions, where stringent conditions may include: 400 mM NaCl, 40 mM PIPES pH 6.4, 1 mM EDTA, 50° C. or 70° C. for 12-16 hours followed by washing. Other conditions, such as physiologically relevant conditions as may be encountered inside an organism, can apply. The skilled person will be able to determine the set of conditions most appropriate for a test of complementarity of two sequences in accordance with the ultimate application of the hybridized nucleotides.

This includes base-pairing of the oligonucleotide or polynucleotide comprising the first nucleotide sequence to the oligonucleotide or polynucleotide comprising the second nucleotide sequence over the entire length of the first and second nucleotide sequence. Such sequences can be referred to as “fully complementary” with respect to each other herein. However, where a first sequence is referred to as “substantially complementary” with respect to a second sequence herein, the two sequences can be fully complementary, or they may form one or more, but preferably not more than 4, 3 or 2 mismatched base pairs upon hybridization, while retaining the ability to hybridize under the conditions most relevant to their ultimate application. However, where two oligonucleotides are designed to form, upon hybridization, one or more single stranded overhangs, such overhangs shall not be regarded as mismatches with regard to the determination of complementarity. For example, a dsRNA comprising one oligonucleotide 21 nucleotides in length and another oligonucleotide 23 nucleotides in length, wherein the longer oligonucleotide comprises a sequence of 21 nucleotides that is fully complementary to the shorter oligonucleotide, may yet be referred to as “fully complementary” for the purposes of the invention.

“Complementary” sequences, as used herein, may also include, or be formed entirely from, non-Watson-Crick base pairs and/or base pairs formed from non-natural and modified nucleotides, in as far as the above requirements with respect to their ability to hybridize are fulfilled.

The terms “complementary”, “fully complementary” and “substantially complementary” herein may be used with respect to the base matching between the sense strand and the antisense strand of a dsRNA, or between the antisense strand of a dsRNA and a target sequence, as will be understood from the context of their use.

As used herein, “essentially identical” when used referring to a first nucleotide sequence in comparison to a second nucleotide sequence means that the first nucleotide sequence is identical to the second nucleotide sequence except for up to one, two or three nucleotide substitutions (e.g. adenosine replaced by uracil).

As used herein, a “subject” refers to a mammalian organism undergoing treatment for a disorder associated with undesired TGF-beta signaling, such as undergoing treatment prophylactically or therapeutically to prevent TGF-beta production. The subject can be any mammal, such as a primate, cow, horse, mouse, rat, dog, pig, goat. In the preferred embodiment, the subject is a human.

As used herein, “target sequence” refers to a contiguous portion of the nucleotide sequence of an mRNA molecule formed during the transcription of a TGF-beta gene, including mRNA that is a product of RNA processing of a primary transcription product.

As used herein, treating a disorder associated with undesired TGF-beta signaling refers to the amelioration of any biological or pathological endpoints that 1) is mediated in part by the unwanted expression or over expression of TGF-beta in the subject and 2) whose outcome can be affected by reducing the level of TGF-beta gene products present.

As used herein, the phrases “therapeutically effective amount” and “prophylactically effective amount” refer to an amount that provides a therapeutic benefit in the treatment, prevention, or management of pain or an overt symptom of pain. The specific amount that is therapeutically effective can be readily determined by ordinary medical practitioner, and may vary depending on factors known in the art, such as, e.g. the type of pain, the patient's history and age, the stage of pain, and the administration of other anti-pain agents.

As used herein, a “pharmaceutical composition” comprises a pharmacologically effective amount of a dsRNA and a pharmaceutically acceptable carrier. As used herein, “pharmacologically effective amount,” “therapeutically effective amount” or simply “effective amount” refers to that amount of an RNA effective to produce the intended pharmacological, therapeutic or preventive result. For example, if a given clinical treatment is considered effective when there is at least a 25% reduction in a measurable parameter associated with a disease or disorder, a therapeutically effective amount of a drug for the treatment of that disease or disorder is the amount necessary to effect at least a 25% reduction in that parameter.

The term “pharmaceutically acceptable carrier” refers to a carrier for administration of a therapeutic agent. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The term specifically excludes cell culture medium. For drugs administered orally, pharmaceutically acceptable carriers include, but are not limited to pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.

As used herein, a “transformed cell” is a cell into which a vector has been introduced from which a dsRNA molecule may be expressed.

Design and Selection of iRNA Agents

The present invention is based on the demonstration of target gene silencing of the TGF-beta gene in vitro following administration of an iRNA agent results in reducing TGF-beta signaling.

Based on these results, the invention specifically provides an iRNA agent that can be used in reducing TGF-beta levels in a cell or organism, particularly for use in reducing undesired TGF-beta signaling, in isolated form and as a pharmaceutical composition described below. Such agents will include a sense strand having at least 15 or more contiguous nucleotides that are complementary to a TGF-beta gene and an antisense strand having at least 15 or more contiguous nucleotides that are complementary to the sense strand sequence. Particularly useful are iRNA agents that comprise a nucleotide sequence from the TGF-beta gene as provided in Table 1 and Table 5.

Other candidate iRNA agents can be designed by performing, for example, a gene walk analysis of the TGF-beta gene that will serve as the iRNA target. Overlapping, adjacent, or closely spaced candidate agents corresponding to all or some of the transcribed region can be generated and tested. Each of the iRNA agents can be tested and evaluated for the ability to down regulate the target gene expression (see below, “Evaluation of Candidate iRNA agents”).

Preferably, the iRNA agents of the present invention are based on and comprise at least 15 or more contiguous nucleotides from one of the iRNA agents shown to be active in Table 1 and Table 5. In such agents, the agent can comprise the entire sequence provided in the table or can comprise 15 or more contiguous residues along with additional nucleotides from contiguous regions of the target gene. Alternatively, an iRNA agent of the instant invention may effect the cleavage of a TGF-beta mRNA within a sequence on the TGF-beta mRNA that is the target sequence of one of the iRNA agents provided in Table 1 and Table 5. The target sequences of the iRNA agents in Table 5 is expressly provided therein, the target sequence of the iRNA agents provided in Table 1 is equal to the sense strand sequence of these agents, minus the 5′-terminal deoxythymidines (and, where applicable, replacing 2′-O-methyl ribonucleotides by ribonucleotides). The skilled person is well aware of how an iRNA agent that cleaves a target mRNA within a given mRNA sequence may be designed. Cleavage of a target mRNA occurs between the two nucleotides hybrized to those in positions 10 and 11, counting 5′ to 3′, of the iRNA agent's antisense strand (Elbashir, S., et al., EMBO J. 2001, 23:6877). Therefore, an iRNA agent may be designed to cleave at a given site by including a sequence in its antisense strand sufficiently complementary to the target mRNA to hybridize to the target mRNA such that 10 nucleotides of the antisense strand are hybridized 3′ to the intended cleavage site on the mRNA, the remainder being hybridized to a sequence 5′ on the target mRNA.

An iRNA agent can be rationally designed based on sequence information and desired characteristics and the information provided in Table 1 and Table 5. For example, an iRNA agent can be designed according to the relative melting temperature of the candidate duplex. Generally, the duplex should have a lower melting temperature at the 5′ end of the antisense strand than at the 3′ end of the antisense strand.

The skilled person is well aware that dsRNAs comprising a duplex structure of between 20 and 23, but specifically 21, base pairs have been hailed as particularly effective in inducing RNA interference (Elbashir et al., EMBO 2001, 20:6877-6888). However, others have found that shorter or longer dsRNAs can be effective as well. In the embodiments described above, by virtue of the nature of the oligonucleotide sequences provided in Table 1 and Table 5, the dsRNAs of the invention can comprise at least one strand of a length of minimally 21 nt. It can be reasonably expected that shorter dsRNAs comprising one of the sequences of Table 1 and Table 5 minus only a few nucleotides on one or both ends may be similarly effective as compared to the dsRNAs described above. Hence, dsRNAs comprising a partial sequence from one of the sequences of Table 1 and Table 5, and differing in their ability to inhibit the expression of a TGF-beta gene in an assay as described herein below by not more than 5, 10, 15, 20, 25, or 30% inhibition from a dsRNA comprising the full sequence, are contemplated by the invention.

Accordingly, the present invention provides iRNA agents comprising a sense strand and antisense strand each comprising a sequence of at least 15, 16, 17, 18, 19, 20, 21 or 23 nucleotides which is essentially identical to, as defined above, a portion of the TGF-beta gene. Exemplified iRNA agents include those that comprise 15 or more contiguous nucleotides from one of the agents provided in Table 1 and Table 5.

The antisense strand of an iRNA agent should be equal to or at least, 15, 16, 17, 18, 19, 25, 29, 40, or 50 nucleotides in length. It should be equal to or less than 50, 40, or 30, nucleotides in length. Preferred ranges are 15-30, 17 to 25, 19 to 23, and 19 to 21 nucleotides in length. Exemplified iRNA agents include those that comprise 15 or more nucleotides from one of the agents in Table 1 and Table 5.

The sense strand of an iRNA agent should be equal to or at least 15, 16 17, 18, 19, 25, 29, 40, or 50 nucleotides in length. It should be equal to or less than 50, 40, or 30 nucleotides in length. Preferred ranges are 15-30, 17 to 25, 19 to 23, and 19 to 21 nucleotides in length. Exemplified iRNA agents include those that comprise 15 or more nucleotides from one of the agents Table 1 and Table 5.

The double stranded portion of an iRNA agent should be equal to or at least, 15, 16 17, 18, 19, 20, 21, 22, 23, 24, 25, 29, 40, or 50 nucleotide pairs in length. It should be equal to or less than 50, 40, or 30 nucleotides pairs in length. Preferred ranges are 15-30, 17 to 25, 19 to 23, and 19 to 21 nucleotides pairs in length.

The agents provided in Table 1 and Table 5 are 21 nucleotides in length for each strand. The iRNA agents contain a 19 nucleotide double stranded region with a 2 nucleotide overhang on each of the 3′ ends of the agent. These agents can be modified as described herein to obtain equivalent agents comprising at least a portion of these sequences (15 or more contiguous nucleotides) and or modifications to the oligonucleotide bases and linkages.

Generally, the iRNA agents of the instant invention include a region of sufficient complementarity to the TGF-beta gene, and are of sufficient length in terms of nucleotides, that the iRNA agent, or a fragment thereof, can mediate down regulation of the specific TGF-beta gene. The antisense strands of the iRNA agents of the present invention are preferably fully complementary to the mRNA sequences of TGF-beta gene. However, it is not necessary that there be perfect complementarity between the iRNA agent and the target, but the correspondence must be sufficient to enable the iRNA agent, or a cleavage product thereof, to direct sequence specific silencing, e.g., by RNAi cleavage of an TGF-beta mRNA.

Therefore, the iRNA agents of the instant invention include agents comprising a sense strand and antisense strand each comprising a sequence of at least 16, 17 or 18 nucleotides which is essentially identical, as defined below, to one of the sequences of a TGF-beta gene such as those agent provided in Table 1 and Table 5, except that not more than 1, 2 or 3 nucleotides per strand, respectively, have been substituted by other nucleotides (e.g. adenosine replaced by uracil), while essentially retaining the ability to inhibit TGF-beta expression in cultured human cells, as defined below. These agents will therefore possess at least 15 or more nucleotides identical to one of the sequences of a TGF-beta gene but 1, 2 or 3 base mismatches with respect to either the target TGF-beta mRNA sequence or between the sense and antisense strand are introduced. Mismatches to the target TGF-beta mRNA sequence, particularly in the antisense strand, are most tolerated in the terminal regions and if present are preferably in a terminal region or regions, e.g., within 6, 5, 4, or 3 nucleotides of a 5′ and/or 3′ terminus, most preferably within 6, 5, 4, or 3 nucleotides of the 5′-terminus of the sense strand or the 3′-terminus of the antisense strand. The sense strand need only be sufficiently complementary with the antisense strand to maintain the overall double stranded character of the molecule.

It is preferred that the sense and antisense strands be chosen such that the iRNA agent includes a single strand or unpaired region at one or both ends of the molecule, such as those exemplified in Table 1 and Table 5. Thus, an iRNA agent contains sense and antisense strands, preferably paired to contain an overhang, e.g., one or two 5′ or 3′ overhangs but preferably a 3′ overhang of 2-3 nucleotides. Most embodiments will have a 3′ overhang. Preferred siRNA agents will have single-stranded overhangs, preferably 3′ overhangs, of 1 to 6, preferably 1 to 4, or more preferably 2 or 3 nucleotides, in length, on one or both ends of the iRNA agent. The overhangs can be the result of one strand being longer than the other, or the result of two strands of the same length being staggered. 5′-ends are preferably phosphorylated.

Moreover, the present inventors have discovered that the presence of only one nucleotide overhang strengthens the interference activity of the dsRNA, without affecting its overall stability. dsRNA having only one overhang has proven particularly stable and effective in vivo, as well as in a variety of cells, cell culture mediums, blood, and serum. Preferably, the single-stranded overhang is located at the 3′-terminal end of the antisense strand or, alternatively, at the 3′-terminal end of the sense strand. The dsRNA may also have a blunt end, preferably located at the 5′-end of the antisense strand. Such dsRNAs have improved stability and inhibitory activity, thus allowing administration at low dosages, i.e., less than 5 mg/kg body weight of the recipient per day. Preferably, the antisense strand of the dsRNA has a nucleotide overhang at the 3′-end, and the 5′-end is blunt. In another embodiment, one or more of the nucleotides in the overhang is replaced with a nucleoside thiophosphate.

Preferred lengths for the duplexed region is between 15 and 30, most preferably 18, 19, 20, 21, 22, and 23 nucleotides in length, e.g., in the siRNA agent range discussed above. Embodiments in which the two strands of the siRNA agent are linked, e.g., covalently linked are also included. Hairpin, or other single strand structures which provide the required double stranded region, and preferably a 3′ overhang are also within the invention.

Evaluation of Candidate iRNA Agents

A candidate iRNA agent can be evaluated for its ability to down regulate target gene expression. For example, a candidate iRNA agent can be provided, and contacted with a cell, e.g. a human cell that expresses TGF-beta. Alternatively, the cell can be transfected with a construct from which a target TGF-beta gene is expressed, thus preventing the need for endogenous TGF-beta expression. The level of target gene expression prior to and following contact with the candidate iRNA agent can be compared, e.g. on an mRNA or protein level. If it is determined that the amount of RNA or protein expressed from the target gene is lower following contact with the iRNA agent, then it can be concluded that the iRNA agent down-regulates target gene expression. The level of target TGF-beta mRNA or TGF-beta protein in the cell or tissue can be determined by any method desired. For example, the level of target RNA can be determined by Northern blot analysis, reverse transcription coupled with polymerase chain reaction (RT-PCR), bDNA analysis, or RNAse protection assay. The level of protein can be determined, for example, by Western blot analysis or immunofluorescence.

Stability Testing, Modification, and Retesting of iRNA Agents

A candidate iRNA agent can be evaluated with respect to stability, e.g., its susceptibility to cleavage by an endonuclease or exonuclease, such as when the iRNA agent is introduced into the body of a subject. Methods can be employed to identify sites that are susceptible to modification, particularly cleavage, e.g., cleavage by a component found in the body of a subject.

When sites susceptible to cleavage are identified, a further iRNA agent can be designed and/or synthesized wherein the potential cleavage site is made resistant to cleavage, e.g. by introduction of a 2′-modification on the site of cleavage, e.g. a 2′-O-methyl group. This further iRNA agent can be retested for stability, and this process may be iterated until an iRNA agent is found exhibiting the desired stability. Table 1 provides a variety of sequence modifications as exemplars, which are nevertheless not to be understood as limiting.

In Vivo Testing

An iRNA agent identified as being capable of inhibiting TGF-beta gene expression can be tested for functionality in vivo in an animal model (e.g., in a mammal, such as in mouse or rat) as shown in the examples. For example, the iRNA agent can be administered to an animal, and the iRNA agent evaluated with respect to its biodistribution, stability, and its ability to inhibit TGF-beta, e.g. lower TGF-beta protein or gene expression.

The iRNA agent can be administered directly to the target tissue, such as by injection, or the iRNA agent can be administered to the animal model in the same manner that it would be administered to a human, e.g. by inhalation, injection or infusion.

The iRNA agent can also be evaluated for its intracellular distribution. The evaluation can include determining whether the iRNA agent was taken up into the cell. The evaluation can also include determining the stability (e.g., the half-life) of the iRNA agent. Evaluation of an iRNA agent in vivo can be facilitated by use of an iRNA agent conjugated to a traceable marker (e.g., a fluorescent marker such as fluorescein; a radioactive label, such as ³⁵S, ³²P, ³³P, or ³H; gold particles; or antigen particles for immunohistochemistry).

The iRNA agent can be evaluated with respect to its ability to down regulate TGF-beta gene expression. Levels of TGF-beta gene expression in vivo can be measured, for example, by in situ hybridization, or by the isolation of RNA from tissue prior to and following exposure to the iRNA agent. Where the animal needs to be sacrificed in order to harvest the tissue, an untreated control animal will serve for comparison. Target TGF-beta mRNA can be detected by any desired method, including but not limited to RT-PCR, Northern blot, branched-DNA assay, or RNAase protection assay. Alternatively, or additionally, TGF-beta gene expression can be monitored by performing Western blot analysis on tissue extracts treated with the iRNA agent.

iRNA Chemistry

Described herein are isolated iRNA agents, e.g., ds RNA agents, that mediate RNAi to inhibit expression of a TGF-beta gene.

RNA agents discussed herein include otherwise unmodified RNA as well as RNA which have been modified, e.g., to improve efficacy, and polymers of nucleoside surrogates. Unmodified RNA refers to a molecule in which the components of the nucleic acid, namely sugars, bases, and phosphate moieties, are the same or essentially the same as that which occur in nature, preferably as occur naturally in the human body. The art has referred to rare or unusual, but naturally occurring, RNAs as modified RNAs, see, e.g., Limbach et al., (1994) Nucleic Acids Res. 22: 2183-2196. Such rare or unusual RNAs, often termed modified RNAs (apparently because these are typically the result of a post-transcriptional modification) are within the term unmodified RNA, as used herein. Modified RNA as used herein refers to a molecule in which one or more of the components of the nucleic acid, namely sugars, bases, and phosphate moieties, are different from that which occurs in nature, preferably different from that which occurs in the human body. While they are referred to as modified “RNAs,” they will of course, because of the modification, include molecules which are not RNAs. Nucleoside surrogates are molecules in which the ribophosphate backbone is replaced with a non-ribophosphate construct that allows the bases to the presented in the correct spatial relationship such that hybridization is substantially similar to what is seen with a ribophosphate backbone, e.g., non-charged mimics of the ribbphosphate backbone. Examples of each of the above are discussed herein.

Modifications described herein can be incorporated into any double-stranded RNA and RNA-like molecule described herein, e.g., an iRNA agent. It may be desirable to modify one or both of the antisense and sense strands of an iRNA agent. As nucleic acids are polymers of subunits or monomers, many of the modifications described below occur at a position which is repeated within a nucleic acid, e.g., a modification of a base, or a phosphate moiety, or the non-linking O of a phosphate moiety. In some cases the modification will occur at all of the subject positions in the nucleic acid but in many, and in fact in most, cases it will not. By way of example, a modification may only occur at a 3′ or 5′ terminal position, may only occur in a terminal region, e.g. at a position on a terminal nucleotide or in the last 2, 3, 4, 5, or 10 nucleotides of a strand. A modification may occur in a double strand region, a single strand region, or in both. E.g., a phosphorothioate modification at a non-linking O position may only occur at one or both termini, may only occur in a terminal regions, e.g., at a position on a terminal nucleotide or in the last 2, 3, 4, 5, or 10 nucleotides of a strand, or may occur in double strand and single strand regions, particularly at termini. Similarly, a modification may occur on the sense strand, antisense strand, or both. In some cases, the sense and antisense strand will have the same modifications or the same class of modifications, but in other cases the sense and antisense strand will have different modifications, e.g., in some cases it may be desirable to modify only one strand, e.g. the sense strand.

Two prime objectives for the introduction of modifications into iRNA agents is their stabilization towards degradation in biological environments and the improvement of pharmacological properties, e.g. pharmacodynamic properties, which are further discussed below. Other suitable modifications to a sugar, base, or backbone of an iRNA agent are described in co-owned PCT Application No. PCT/US2004/01193, filed Jan. 16, 2004. An iRNA agent can include a non-naturally occurring base, such as the bases described in co-owned PCT Application No. PCT/US2004/011822, filed Apr. 16, 2004. An iRNA agent can include a non-naturally occurring sugar, such as a non-carbohydrate cyclic carrier molecule. Exemplary features of non-naturally occurring sugars for use in iRNA agents are described in co-owned PCT Application No. PCT/US2004/11829 filed Apr. 16, 2003.

An iRNA agent can include an internucleotide linkage (e.g., the chiral phosphorothioate linkage) useful for increasing nuclease resistance. In addition, or in the alternative, an iRNA agent can include a ribose mimic for increased nuclease resistance. Exemplary internucleotide linkages and ribose mimics for increased nuclease resistance are described in co-owned PCT Application No. PCT/US2004/07070 filed on Mar. 8, 2004.

An iRNA agent can include ligand-conjugated monomer subunits and monomers for oligonucleotide synthesis. Exemplary monomers are described in co-owned U.S. application Ser. No. 10/916,185, filed on Aug. 10, 2004.

An iRNA agent can have a ZXY structure, such as is described in co-owned PCT Application No. PCT/US2004/07070 filed on Mar. 8, 2004.

An iRNA agent can be complexed with an amphipathic moiety. Exemplary amphipathic moieties for use with iRNA agents are described in co-owned PCT Application No. PCT/US2004/07070 filed on Mar. 8, 2004.

In another embodiment, the iRNA agent can be complexed to a delivery agent that features a modular complex. The complex can include a carrier agent linked to one or more of (preferably two or more, more preferably all three of): (a) a condensing agent (e.g., an agent capable of attracting, e.g., binding, a nucleic acid, e.g., through ionic or electrostatic interactions); (b) a fusogenic agent (e.g., an agent capable of fusing and/or being transported through a cell membrane); and (c) a targeting group, e.g., a cell or tissue targeting agent, e.g., a lectin, glycoprotein, lipid or protein, e.g., an antibody, that binds to a specified cell type. iRNA agents complexed to a delivery agent are described in co-owned PCT Application No. PCT/US2004/07070 filed on Mar. 8, 2004.

An iRNA agent can have non-canonical pairings, such as between the sense and antisense sequences of the iRNA duplex. Exemplary features of non-canonical iRNA agents are described in co-owned PCT Application No. PCT/US2004/07070 filed on Mar. 8, 2004.

Enhanced Nuclease Resistance

An iRNA agent, e.g., an iRNA agent that targets TGF-beta, can have enhanced resistance to nucleases.

For increased nuclease resistance and/or binding affinity to the target, an iRNA agent, e.g., the sense and/or antisense strands of the iRNA agent, can include, for example, 2′-modified ribose units and/or phosphorothioate linkages. E.g., the 2′ hydroxyl group (OH) can be modified or replaced with a number of different “oxy” or “deoxy” substituents.

Examples of “oxy”-2′ hydroxyl group modifications include alkoxy or aryloxy (OR, e.g., R═H, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl or sugar); polyethyleneglycols (PEG), O(CH₂CH₂O)_(n)CH₂CH₂OR; “locked” nucleic acids (LNA) in which the 2′ hydroxyl is connected, e.g., by a methylene bridge, to the 4′ carbon of the same ribose sugar; O-AMINE and aminoalkoxy, O(CH₂)_(n)AMINE, (e.g., AMINE=NH₂; alkylamino, dialkylamino, heterocyclyl amino, arylamino, diaryl amino, heteroaryl amino, or diheteroaryl amino, ethylene diamine, polyamino). It is noteworthy that oligonucleotides containing only the methoxyethyl group (MOE), (OCH₂CH₂OCH₃, a PEG derivative), exhibit nuclease stabilities comparable to those modified with the robust phosphorothioate modification.

“Deoxy” modifications include hydrogen (i.e. deoxyribose sugars, which are of particular relevance to the overhang portions of partially ds RNA); halo (e.g., fluoro); amino (e.g. NH2; alkylamino, dialkylamino, heterocyclyl, arylamino, diaryl amino, heteroaryl amino, diheteroaryl amino, or amino acid); NH(CH₂CH₂NH)_(n)CH₂CH₂-AMINE (AMINE=NH₂; alkylamino, dialkylamino, heterocyclyl amino, arylamino, diaryl amino, heteroaryl amino, or diheteroaryl amino), —NHC(O)R(R=alkyl, cycloalkyl, aryl, aralkyl, heteroaryl or sugar), cyano; mercapto; alkyl-thio-alkyl; thioalkoxy; and alkyl, cycloalkyl, aryl, alkenyl and alkynyl, which may be optionally substituted with e.g., an amino functionality.

Preferred substituents are 2′-methoxyethyl, 2′-OCH3, 2′-O-allyl, 2′-C-allyl, and 2′-fluoro.

One way to increase resistance is to identify cleavage sites and modify such sites to inhibit cleavage, as described in co-owned U.S. Application No. 60/559,917, filed on May 4, 2004. For example, the dinucleotides 5′-ua-3′, 5′-ca-3′,5′-ug-3′,5′-uu-3′, or 5′-cc-3′ can serve as cleavage sites. In certain embodiments, all the pyrimidines of an iRNA agent carry a 2′-modification in either the sense strand, the antisense strand, or both strands, and the iRNA agent therefore has enhanced resistance to endonucleases. Enhanced nuclease resistance can also be achieved by modifying the 5′ nucleotide, resulting, for example, in at least one 5′-uridine-adenine-3′ (5′-ua-3′) dinucleotide wherein the uridine is a 2′-modified nucleotide; at least one 5′-cytidine-adenine-3′ (5′-ca-3′) dinucleotide, wherein the 5′-cytidine is a 2′-modified nucleotide; at least one 5′-uridine-guanine-3′ (5′-ug-3′) dinucleotide, wherein the 5′-uridine is a 2′-modified nucleotide; at least one 5′-uridine-uridine-3′ (5′-uu-3′) dinucleotide, wherein the 5′-uridine is a 2′-modified nucleotide; or at least one 5′-cytidine-cytidine-3′ (5′-cc-3′) dinucleotide, wherein the 5′-cytidine is a 2′-modified nucleotide, as described in co-owned International Application No. PCT/US2005/018931, filed on May 27, 2005. The iRNA agent can include at least 2, at least 3, at least 4 or at least 5 of such dinucleotides. In a particularly preferred embodiment, the 5′ nucleotide in all occurrences of the sequence motifs 5′-ua-3′ and 5′-ca-3′ in either the sense strand, the antisense strand, or both strands is a modified nucleotide. Preferably, the 5′ nucleotide in all occurrences of the sequence motifs 5′-ua-3′,5′-ca-3′ and 5′-ug-3′ in either the sense strand, the antisense strand, or both strands is a modified nucleotide. More preferably, all pyrimidine nucleotides in the sense strand are modified nucleotides, and the 5′ nucleotide in all occurrences of the sequence motifs 5 ′-ua-3′ and 5 ′-ca-3′ in the antisense strand are modified nucleotides, or where the antisense strand does comprise neither of a 5′-ua-3′ and a 5′-ca-3′ motif, in all occurrences of the sequence motif 5′-ug-3′. Preferably, sites particularly prone to nuclease degradation are first determined, e.g. by mass spectrometry of degradation products, and only those sites are sequentially modified until a desired level of stability is attained.

To maximize nuclease resistance, the 2′ modifications can be used in combination with one or more phosphate linker modifications (e.g., phosphorothioate), as further described below. The so-called “chimeric” oligonucleotides are those that contain two or more different modifications. Preferably, phosphate linker modifications are located near the 3′- and/or 5′-end of either or both strands, or at or near sites particularly prone to degradative attack.

The inclusion of furanose sugars in the oligonucleotide backbone can also decrease endonucleolytic cleavage. An iRNA agent can be further modified by including a 3′ cationic group, or by inverting the nucleoside at the 3′-terminus with a 3′-3′ linkage. In another alternative, the 3′-terminus can be blocked with an aminoalkyl group, e.g., a 3′ C5-aminoalkyl dT. Other 3′ conjugates can inhibit 3′-5′ exonucleolytic cleavage. While not being bound by theory, a 3′ conjugate, such as naproxen or ibuprofen, may inhibit exonucleolytic cleavage by sterically blocking the exonuclease from binding to the 3′-end of oligonucleotide. Even small alkyl chains, aryl groups, or heterocyclic conjugates or modified sugars (D-ribose, deoxyribose, glucose etc.) can block 3′-5′-exonucleases.

Similarly, 5′ conjugates can inhibit 5′-3′ exonucleolytic cleavage. While not being bound by theory, a 5′ conjugate, such as naproxen or ibuprofen, may inhibit exonucleolytic cleavage by sterically blocking the exonuclease from binding to the 5′-end of oligonucleotide. Even small alkyl chains, aryl groups, or heterocyclic conjugates or modified sugars (D-ribose, deoxyribose, glucose etc.) can block 3′-5′-exonucleases.

An iRNA agent can have increased resistance to nucleases when a duplexed iRNA agent includes a single-stranded nucleotide overhang on at least one end. In preferred embodiments, the nucleotide overhang includes 1 to 4, preferably 2 to 3, unpaired nucleotides. In a preferred embodiment, the unpaired nucleotide of the single-stranded overhang that is directly adjacent to the terminal nucleotide pair contains a purine base, and the terminal nucleotide pair is a G-C pair, or at least two of the last four complementary nucleotide pairs are G-C pairs. In further embodiments, the nucleotide overhang may have 1 or 2 unpaired nucleotides, and in an exemplary embodiment the nucleotide overhang is 5′-GC-3′. In preferred embodiments, the nucleotide overhang is on the 3′-end of the antisense strand. In one embodiment, the iRNA agent includes the motif 5′-CGC-3′ on the 3′-end of the antisense strand, such that a 2-nt overhang 5′-GC-3′ is formed.

Thus, an iRNA agent can include modifications so as to inhibit degradation, e.g., by nucleases, e.g., endonucleases or exonucleases, found in the body of a subject. These monomers are referred to herein as NRMs, or Nuclease Resistance promoting Monomers, the corresponding modifications as NRM modifications. In many cases these modifications will modulate other properties of the iRNA agent as well, e.g., the ability to interact with a protein, e.g., a transport protein, e.g., serum albumin, or a member of the RISC, or the ability of the first and second sequences to form a duplex with one another or to form a duplex with another sequence, e.g., a target molecule.

One or more different NRM modifications can be introduced into an iRNA agent or into a sequence of an iRNA agent. An NRM modification can be used more than once in a sequence or in an iRNA agent.

NRM modifications include some which can be placed only at the terminus and others which can go at any position. Some NRM modifications that can inhibit hybridization are preferably used only in terminal regions, and more preferably not at the cleavage site or in the cleavage region of a sequence which targets a subject sequence or gene, particularly on the antisense strand. They can be used anywhere in a sense strand, provided that sufficient hybridization between the two strands of the ds iRNA agent is maintained. In some embodiments it is desirable to put the NRM at the cleavage site or in the cleavage region of a sense strand, as it can minimize off-target silencing.

In most cases, the NRM modifications will be distributed differently depending on whether they are comprised on a sense or antisense strand. If on an antisense strand, modifications which interfere with or inhibit endonuclease cleavage should not be inserted in the region which is subject to RISC mediated cleavage, e.g., the cleavage site or the cleavage region (As described in Elbashir et al., 2001, Genes and Dev. 15: 188, hereby incorporated by reference). Cleavage of the target occurs about in the middle of a 20 or 21 nt antisense strand, or about 10 or 11 nucleotides upstream of the first nucleotide on the target mRNA which is complementary to the antisense strand. As used herein cleavage site refers to the nucleotides on either side of the site of cleavage, on the target mRNA or on the iRNA agent strand which hybridizes to it. Cleavage region means the nucleotides within 1, 2, or 3 nucleotides of the cleavage site, in either direction.

Such modifications can be introduced into the terminal regions, e.g., at the terminal position or with 2, 3, 4, or 5 positions of the terminus, of a sequence which targets or a sequence which does not target a sequence in the subject.

In a particular embodiment, the 5′-end of the antisense strand and the 3′-end of the sense strand are chemically linked via a hexaethylene glycol linker. In another embodiment, at least one nucleotide of the dsRNA comprises a phosphorothioate or phosphorodithioate groups. The chemical bond at the ends of the dsRNA is preferably formed by triple-helix bonds.

In certain embodiments, a chemical bond may be formed by means of one or several bonding groups, wherein such bonding groups are preferably poly-(oxyphosphinicooxy-1,3-propandiol)- and/or polyethylene glycol chains. In other embodiments, a chemical bond may also be formed by means of purine analogs introduced into the double-stranded structure instead of purines. In further embodiments, a chemical bond may be formed by azabenzene units introduced into the double-stranded structure. In still further embodiments, a chemical bond may be formed by branched nucleotide analogs instead of nucleotides introduced into the double-stranded structure. In certain embodiments, a chemical bond may be induced by ultraviolet light.

Teachings regarding the synthesis of particular modified oligonucleotides may be found in the following U.S. patents: U.S. Pat. Nos. 5,138,045 and 5,218,105, drawn to polyamine conjugated oligonucleotides; U.S. Pat. No. 5,212,295, drawn to monomers for the preparation of oligonucleotides having chiral phosphorus linkages; U.S. Pat. Nos. 5,378,825 and 5,541,307, drawn to oligonucleotides having modified backbones; U.S. Pat. No. 5,386,023, drawn to backbone-modified oligonucleotides and the preparation thereof through reductive coupling; U.S. Pat. No. 5,457,191, drawn to modified nucleobases based on the 3-deazapurine ring system and methods of synthesis thereof; U.S. Pat. No. 5,459,255, drawn to modified nucleobases based on N-2 substituted purines; U.S. Pat. No. 5,521,302, drawn to processes for preparing oligonucleotides having chiral phosphorus linkages; U.S. Pat. No. 5,539,082, drawn to peptide nucleic acids; U.S. Pat. No. 5,554,746, drawn to oligonucleotides having P-lactam backbones; U.S. Pat. No. 5,571,902, drawn to methods and materials for the synthesis of oligonucleotides; U.S. Pat. No. 5,578,718, drawn to nucleosides having alkylthio groups, wherein such groups may be used as linkers to other moieties attached at any of a variety of positions of the nucleoside; U.S. Pat. Nos. 5,587,361 and 5,599,797, drawn to oligonucleotides having phosphorothioate linkages of high chiral purity; U.S. Pat. No. 5,506,351, drawn to processes for the preparation of 2′-O-alkyl guanosine and related compounds, including 2,6-diaminopurine compounds; U.S. Pat. No. 5,587,469, drawn to oligonucleotides having N-2 substituted purines; U.S. Pat. No. 5,587,470, drawn to oligonucleotides having 3-deazapurines; U.S. Pat. No. 5,223,168, and U.S. Pat. No. 5,608,046, both drawn to conjugated 4′-desmethyl nucleoside analogs; U.S. Pat. Nos. 5,602,240, and 5,610,289, drawn to backbone-modified oligonucleotide analogs; U.S. Pat. Nos. 6,262,241, and 5,459,255, drawn to, inter alia, methods of synthesizing 2′-fluoro-oligonucleotides.

In some preferred embodiments, functionalized nucleoside sequences of the invention possessing an amino group at the 5′-terminus are prepared using a DNA synthesizer, and then reacted with an active ester derivative of a selected ligand. Active ester derivatives are well known to those skilled in the art. Representative active esters include N-hydrosuccinimide esters, tetrafluorophenolic esters, pentafluorophenolic esters and pentachlorophenolic esters. The reaction of the amino group and the active ester produces an oligonucleotide in which the selected ligand is attached to the 5′-position through a linking group. The amino group at the 5′-terminus can be prepared utilizing a 5′-Amino-Modifier C6 reagent. In a preferred embodiment, ligand molecules may be conjugated to oligonucleotides at the 5′-position by the use of a ligand-nucleoside phosphoramidite wherein the ligand is linked to the 5′-hydroxy group directly or indirectly via a linker. Such ligand-nucleoside phosphoramidites are typically used at the end of an automated synthesis procedure to provide a ligand-conjugated oligonucleotide bearing the ligand at the 5′-terminus.

In many cases, protecting groups are used during the preparation of the compounds of the invention. As used herein, the term “protected” means that the indicated moiety has a protecting group appended thereon. In some preferred embodiments of the invention, compounds contain one or more protecting groups. A wide variety of protecting groups can be employed in the methods of the invention. In general, protecting groups render chemical functionalities inert to specific reaction conditions, and can be appended to and removed from such functionalities in a molecule without substantially damaging the remainder of the molecule.

Representative hydroxyl protecting groups, for example, are disclosed by Beaucage et al. (Tetrahedron, 1992, 48:2223-23.11). Further hydroxyl protecting groups, as well as other representative protecting groups, are disclosed in Greene and Wuts, Protective Groups in Organic Synthesis, Chapter 2, 2d ed., John Wiley & Sons, New York, 1991, and Oligonucleotides And Analogues A Practical Approach, Ekstein, F. Ed., IRL Press, N.Y, 1991.

Examples of hydroxyl protecting groups include, but are not limited to, t-butyl, t-butoxymethyl, methoxymethyl, tetrahydropyranyl, 1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, 2-trimethylsilylethyl, p-chlorophenyl, 2,4-dinitrophenyl, benzyl, 2,6-dichlorobenzyl, diphenylmethyl, p,p′-dinitrobenzhydryl, p-nitrobenzyl, triphenylmethyl, uimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, triphenylsilyl, benzoylformate, acetate, chloroacetate, trichloroacetate, trifluoroacetate, pivaloate, benzoate, p-phenylbenzoate, 9-fluorenylmethyl carbonate, mesylate and tosylate.

Amino-protecting groups stable to acid treatment are selectively removed with base treatment, and are used to make reactive amino groups selectively available for substitution. Examples of such groups are the Fmoc (E. Atherton and R. C. Sheppard in The Peptides, S. Udenfriend, J. Meienhofer, Eds., Academic Press, Orlando, 1987, volume 9, p. 1) and various substituted sulfonylethyl carbamates exemplified by the Nsc group (Samukov et al., Tetrahedron Lett., 1994, 35:7821; Verhart and Tesser, Rec. Trav. Chim. Pays-Bas, 1987, 107:621).

Additional amino-protecting groups include, but are not limited to, carbamate protecting groups, such as 2-trimethylsilylethoxycarbonyl (Teoc), 1-methyl-1-(4-biphenylyl)ethoxycarbonyl (Bpoc), t-butoxycarbonyl (BOC), allyloxycarbonyl (Alloc), 9-fluorenylmethyloxycarbonyl (Fmoc), and benzyloxycarbonyl (Cbz); amide protecting groups, such as formyl, acetyl, trihaloacetyl, benzoyl, and nitrophenylacetyl; sulfonamide protecting groups, such as 2-nitrobenzenesulfonyl; and imine and cyclic imide protecting groups, such as phthalimido and dithiasuccinoyl. Equivalents of these amino-protecting groups are also encompassed by the compounds and methods of the invention.

Many solid supports are commercially available and one of ordinary skill in the art can readily select a solid support to be used in the solid-phase synthesis steps. In certain embodiments, a universal support is used. A universal support allows for preparation of oligonucleotides having unusual or modified nucleotides located at the 3′-terminus of the oligonucleotide. Universal Support 500 and Universal Support II are universal supports that are commercially available from Glen Research, 22825 Davis Drive, Sterling, Va. For further details about universal supports see Scott et al., Innovations and Perspectives in solid-phase Synthesis, 3rd International Symposium, 1994, Ed. Roger Epton, Mayflower Worldwide, 115-124]; Azhayev, A. V. Tetrahedron 1999, 55, 787-800; and Azhayev and Antopolsky Tetrahedron 2001, 57, 4977-4986. In addition, it has been reported that the oligonucleotide can be cleaved from the universal support under milder reaction conditions when oligonucleotide is bonded to the solid support via a syn-1,2-acetoxyphosphate group which more readily undergoes basic hydrolysis. See Guzaev, A. I.; Manoharan, M. J. Am. Chem. Soc. 2003, 125, 2380.

Ligand Conjugates

The properties of an iRNA agent, including its pharmacological properties, can be influenced and tailored, for example, by the introduction of ligands, e.g. tethered ligands.

A wide variety of entities, e.g., ligands, can be tethered to an iRNA agent, e.g., to the carrier of a ligand-conjugated monomer subunit. Examples are described below in the context of a ligand-conjugated monomer subunit but that is only preferred, entities can be coupled at other points to an iRNA agent.

Preferred moieties are ligands, which are coupled, preferably covalently, either directly or indirectly via an intervening tether, to the carrier. In preferred embodiments, the ligand is attached to the carrier via an intervening tether. The ligand or tethered ligand may be present on the ligand-conjugated monomer when the ligand-conjugated monomer is incorporated into the growing strand. In some embodiments, the ligand may be incorporated into a “precursor” ligand-conjugated monomer subunit after a “precursor” ligand-conjugated monomer subunit has been incorporated into the growing strand. For example, a monomer having, e.g., an amino-terminated tether, e.g., TAP—(CH₂)_(n)NH₂ may be incorporated into a growing sense or antisense strand. In a subsequent operation, i.e., after incorporation of the precursor monomer subunit into the strand, a′ ligand having an electrophilic group, e.g., a pentafluorophenyl ester or aldehyde group, can subsequently be attached to the precursor ligand-conjugated monomer by coupling the electrophilic group of the ligand with the terminal nucleophilic group of the precursor ligand-conjugated monomer subunit tether.

In preferred embodiments, a ligand alters the distribution, targeting or lifetime of an iRNA agent into which it is incorporated. In preferred embodiments a ligand provides an enhanced affinity for a selected target, e.g., molecule, cell or cell type, compartment, e.g., a cellular or organ compartment, tissue, organ or region of the body, as, e.g., compared to a species absent such a ligand.

Preferred ligands can improve transport, hybridization, and specificity properties and may also improve nuclease resistance of the resultant natural or modified oligoribonucleotide, or a polymeric molecule comprising any combination of monomers described herein and/or natural or modified ribonucleotides.

Ligands in general can include therapeutic modifiers, e.g., for enhancing uptake; diagnostic compounds or reporter groups e.g., for monitoring distribution; cross-linking agents; nuclease-resistance conferring moieties; and natural or unusual nucleobases. General examples include lipophilic moleculeses, lipids, lectins, steroids (e.g.,uvaol, hecigenin, diosgenin), terpenes (e.g., triterpenes, e.g., sarsasapogenin, Friedelin, epifriedelanol derivatized lithocholic acid), vitamins, carbohydrates (e.g., a dextran, pullulan, chitin, chitosan, inulin, cyclodextrin or hyaluronic acid), proteins, protein binding agents, integrin targeting molecules,polycationics, peptides, polyamines, and peptide mimics.

The ligand may be a naturally occurring or recombinant or synthetic molecule, such as a synthetic polymer, e.g., a synthetic polyamino acid. Examples of polyamino acids include polyamino acid is a polylysine (PLL), poly L-aspartic acid, poly L-glutamic acid, styrene-maleic acid anhydride copolymer, poly(L-lactide-co-glycolied) copolymer, divinyl ether-maleic anhydride copolymer, N-(2-hydroxypropyl)methacrylamide copolymer (HMPA), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyurethane, poly(2-ethylacrylic acid), N-isopropylacrylamide polymers, or polyphosphazine. Example of polyamines include: polyethylenimine, polylysine (PLL), spermine, spermidine, polyamine, pseudopeptide-polyamine, peptidomimetic polyamine, dendrimer polyamine, arginine, amidine, protamine, cationic moieties, e.g., cationic lipid, cationic porphyrin, quaternary salt of a polyamine, or an alpha helical peptide.

Ligands can also include targeting groups, e.g., a cell or tissue targeting agent, e.g., a thyrotropin, melanotropin, surfactant protein A, Mucin carbohydrate, a glycosylated polyaminoacid, transferrin, bisphosphonate, polyglutamate, polyaspartate, or an RGD peptide or RGD peptide mimetic.

Ligands can be proteins, e.g., glycoproteins, lipoproteins, e.g. low density lipoprotein (LDL), or albumins, e.g. human serum albumin (HSA), or peptides, e.g., molecules having a specific affinity for a co-ligand, or antibodies e.g., an antibody, that binds to a specified cell type such as a cancer cell, endothelial cell, or bone cell. Ligands may also include hormones and hormone receptors. They can also include non-peptidic species, such as cofactors, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-glucosamine, multivalent mannose, or multivalent fucose. The ligand can be, for example, a lipopolysaccharide, an activator of p38 MAP kinase, or an activator of NF-κB.

The ligand can be a substance, e.g, a drug, which can increase the uptake of the iRNA agent into the cell, for example, by disrupting the cell's cytoskeleton, e.g., by disrupting the cell's microtubules, microfilaments, and/or intermediate filaments. The drug can be, for example, taxon, vincristine, vinblastine, cytochalasin, nocodazole, japlakinolide, latrunculin A, phalloidin, swinholide A, indanocine, or myoservin.

In one aspect, the ligand is a lipid or lipid-based molecule. Such a lipid or lipid-based molecule preferably binds a serum protein, e.g., human serum albumin (HSA). An HSA binding ligand allows for distribution of the conjugate to a target tissue, e.g., liver tissue, including parenchymal cells of the liver. Other molecules that can bind HSA can also be used as ligands. For example, neproxin or aspirin can be used. A lipid or lipid-based ligand can (a) increase resistance to degradation of the conjugate, (b) increase targeting or transport into a target cell or cell membrane, and/or (c) can be used to adjust binding to a serum protein, e.g., HSA.

A lipid based ligand can be used to modulate, e.g., control the binding of the conjugate to a target tissue. For example, a lipid or lipid-based ligand that binds to HSA more strongly will be less likely to be targeted to the kidney and therefore less likely to be cleared from the body. A lipid or lipid-based ligand that binds to HSA less strongly can be used to target the conjugate to the kidney.

In a preferred embodiment, the lipid based ligand binds HSA. Preferably, it binds HSA with a sufficient affinity such that the conjugate will be preferably distributed to a non-kidney tissue. However, it is preferred that the affinity not be so strong that the HSA-ligand binding cannot be reversed.

In another aspect, the ligand is a moiety, e.g., a vitamin or nutrient, which is taken up by a target cell, e.g., a proliferating cell. These are particularly useful for treating disorders characterized by unwanted cell proliferation, e.g., of the malignant or non-malignant type, e.g., cancer cells. Exemplary vitamins include vitamin A, E, and K. Other exemplary vitamins include the B vitamins, e.g., folic acid, B12, riboflavin, biotin, pyridoxal or other vitamins or nutrients taken up by cancer cells.

In another aspect, the ligand is a cell-permeation agent, preferably a helical cell-permeation agent. Preferably, the agent is amphipathic. An exemplary agent is a peptide such as that or antennapedia. If the agent is a peptide, it can be modified, including a peptidylmimetic, invertomers, non-peptide or pseudo-peptide linkages, and use of D-amino acids. The helical agent is preferably an alpha-helical agent, which preferably has a lipophilic and a lipophobic phase.

Backbone Modifications

Specific examples of preferred modified oligonucleotides envisioned for use in the ligand-conjugated oligonucleotides of the invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined here, oligonucleotides having modified backbones or internucleoside linkages include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of the invention, modified oligonucleotides that do not have a phosphorus atom in their intersugar backbone can also be considered to be oligonucleosides.

Specific oligonucleotide chemical modifications are described below. It is not necessary for all positions in a given compound to be uniformly modified. Conversely, more than one modifications may be incorporated in a single dsRNA compound or even in a single nucleotide thereof.

Preferred modified internucleoside linkages or backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3′-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3′-5′ linkages, 2′-5′ linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3′-5′ to 5′-3′ or 2′-5′ to 5′-2′. Various salts, salts and free-acid forms are also included.

Representative United States Patents relating to the preparation of the above phosphorus-atom-containing linkages include, but are not limited to, U.S. Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361;

5,625,050; and 5,697,248, each of which is herein incorporated by reference.

Preferred modified internucleoside linkages or backbones that do not include a phosphorus atom therein (i.e., oligonucleosides) have backbones that are formed by short chain alkyl or cycloalkyl intersugar linkages, mixed heteroatom and alkyl or cycloalkyl intersugar linkages, or one or more short chain heteroatomic or heterocyclic intersugar linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, 0, S and CH₂ component parts.

Representative United States patents relating to the preparation of the above oligonucleosides include, but are not limited to, U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, each of which is herein incorporated by reference.

5′-Terminal Modifications

In preferred embodiments, iRNA agents are 5′ phosphorylated or include a phosphoryl analog at the 5′ prime terminus, e.g. 5′ prime terminus of the antisense strand. 5′-phosphate modifications of the antisense strand include those which are compatible with RISC mediated gene silencing. Suitable modifications include: 5′-monophosphate ((HO)2(O)P-O-5′); 5′-diphosphate ((HO)2(O)P—O—P(HO)(O)—O-5′); 5′-triphosphate ((HO)2(O)P—O—(HO)(O)P—O—P(HO)(O)—O-5′); 5′-guanosine cap (7-methylated or non-methylated) (7m-G-O-5′-(HO)(O)P—O—(HO)(O)P—O—P(HO)(O)—O-5′); 5′-adenosine cap (Appp), and any modified or unmodified nucleotide cap structure. Other suitable 5′-phosphate modifications will be known to the skilled person.

The sense strand can be modified in order to inactivate the sense strand and prevent formation of an active RISC, thereby potentially reducing off-target effects. This can be accomplished by a modification which prevents 5′-phosphorylation of the sense strand, e.g., by modification with a 5′-O-methyl ribonucleotide (see Nykänen et al., (2001) ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 107, 309-321.) Other modifications which prevent phosphorylation can also be used, e.g., simply substituting the 5′-OH by H rather than O—Me. Alternatively, a large bulky group may be added to the 5′-phosphate turning it into a phosphodiester linkage.

Disorders and Diseases Associated with Undesired TGF-Beta Signaling

Diseases that can be treated in accordance with the present invention include, without limitation, kidney disorders associated with undesired TGF-beta signaling and excessive fibrosis and/or sclerosis, such as glomerulonephritis (GN) of all etiologies, e.g., mesangial proliferative GN, immune GN, and crescentic GN; diabetic nephropathy; renal interstitial fibrosis and all causes of renal interstitial fibrosis, including hypertension; renal fibrosis resulting from complications of drug exposure, including cyclosporin treatment of transplant recipients, e.g. cyclosporin treatment; HIV-associated nephropathy, transplant necropathy. The invention further includes the treatment of hepatic diseases associated with excessive scarring and progressive sclerosis, including cirrhosis due to all etiologies, disorders of the biliary tree, and hepatic dysfunction attributable to infections such as infection with hepatitis virus or parasites; pulmonary fibrosis and symptoms associates with pulmonary fibrosis with consequential loss of gas exchange or ability to efficiently move air into and out of the lungs, including adult respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD); idiopathic pulmonary fibrosis (IPF), acute lung injury (ALI), or pulmonary fibrosis due to infectious or toxic agents such as smoke, chemicals, allergens, or autoimmune diseases, such as systemic lupus erythematosus and scleroderma, chemical contact, or allergies. Fibroproliferative diseases targeted by the agents, pharmaceutical compositions, and treatment methods herein further include cardiovascular diseases, such as congestive heart failure, dilated cardiomyopathy, myocarditis, or vascular stenosis associated with atherosclerosis, angioplasty treatment, or surgical incisions or mechanical trauma. The invention also includes the treatment of all collagen vascular disorders of a chronic or persistent nature including progressive systemic sclerosis, polymyositis, scleroderma, dermatomyositis, fascists, or Raynaud's syndrome, or arthritic conditions such as rheumatoid arthritis; eye diseases associated with fibroproliferative states, including proliferative vitreoretinopathy of any etiology or fibrosis associated with ocular surgery such as treatment of glaucoma, retinal reattachment, cataract extraction, or drainage procedures of any kind; excessive or hypertrophic scar formation in the dermis occurring during wound healing resulting from trauma or surgical wounds.

While the above list is not meant in any way limiting, the treatment of all the above disorders and diseases are contemplated by the invention.

Delivery of iRNA Agents to Tissues and Cells

Formulation

For ease of exposition, the formulations, compositions, and methods in this section are discussed largely with regard to unmodified iRNA agents. It should be understood, however, that these formulations, compositions, and methods can be practiced with other iRNA agents, e.g., modified iRNA agents, and such practice is within the invention.

The term “therapeutically effective amount” is the amount present in the composition that is needed to provide the desired level of drug in the subject to be treated to give the anticipated physiological response.

The term “physiologically effective amount” is that amount delivered to a subject to give the desired palliative or curative effect.

The term “co-administration” refers to administering to a subject two or more agents, and in particular two or more iRNA agents. The agents can be contained in a single pharmaceutical composition and be administered at the same time, or the agents can be contained in separate formulation and administered serially to a subject. So long as the two agents can be detected in the subject at the same time, the two agents are said to be co-administered.

In the present methods, the iRNA agent can be administered to the subject either as naked iRNA agent, in conjunction with a delivery reagent, or as a recombinant plasmid or viral vector which expresses the iRNA agent. Preferably, the iRNA agent is administered as naked iRNA.

The iRNA agents described herein can be formulated for administration to a subject, preferably for administration locally to a site of fibrosis or sclerosis, or parenterally, e.g. via injection.

A formulated iRNA agent composition can assume a variety of states. In some examples, the composition is at least partially crystalline, uniformly crystalline, and/or anhydrous (e.g., less than 80, 50, 30, 20, or 10% water). In other examples, the composition is amorphous, such as a wax. In another example, the iRNA agent is in an aqueous phase, e.g., in a solution that includes water, this form being the preferred form for administration via inhalation. The aqueous phase may contain other solvents or excipients, e.g. ethanol.

The aqueous phase or the crystalline compositions can be incorporated into a delivery vehicle, e.g., a liposome (particularly for the aqueous phase), or a particle (e.g., a microparticle as can be appropriate for a crystalline composition). Generally, the iRNA agent composition is formulated in a manner that is compatible with the intended method of administration.

Formulations for direct injection and parenteral administration are well known in the art. Such formulation may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives. For intravenous use, the total concentration of solutes should be controlled to render the preparation isotonic.

The nucleic acid molecules of the present invention can also be co-administered to a subject in combination with other therapeutic compounds to increase the overall therapeutic effect. The use of multiple compounds to treat an indication can increase the beneficial effects while reducing the presence of side effects.

An iRNA agent preparation can be formulated in combination with another agent, e.g., another therapeutic agent or an agent that stabilizes an iRNA agent, e.g., a protein that complexes with the iRNA agent to form an iRNP. Still other agents include chelators, e.g., EDTA (e.g., to remove divalent cations such as Mg²⁺), salts, RNAse inhibitors (e.g., a broad specificity RNAse inhibitor such as RNAsin) and so forth.

In one embodiment, the iRNA agent preparation includes another iRNA agent, e.g., a second iRNA agent that can mediate RNAi with respect to a second gene. Still other. preparations can include at least three, five, ten, twenty, fifty, or a hundred or more different iRNA species. In some embodiments, the agents are directed to the same gene but different target sequences. In another embodiment, each iRNA agent is directed to a different gene, e.g. TGF-beta.

An iRNA agent can be incorporated into pharmaceutical compositions suitable for administration. For example, compositions can include one or more iRNA agents and a pharmaceutically acceptable carrier.

The iRNA agents featured by the invention are preferably formulated as pharmaceutical compositions prior to administering to a subject, according to techniques known in the art. Pharmaceutical compositions of the present invention are characterized as being at least sterile and pyrogen-free. As used herein, “pharmaceutical formulations” include formulations for human and veterinary use. Methods for preparing pharmaceutical compositions of the invention are within the skill in the art, for example as described in Remington's Pharmaceutical Science, 18th ed., Mack Publishing Company, Easton, Pa. (1990), and The Science and Practice of Pharmacy, 2003, Gennaro et al., the entire disclosures of which are herein incorporated by reference.

The present pharmaceutical formulations comprise an iRNA agent of the invention (e.g., 0.1 to 90% by weight), or a physiologically acceptable salt thereof, mixed with a physiologically acceptable carrier medium. Preferred physiologically acceptable carrier media are water, buffered water, normal saline, 0.4% saline, 0.3% glycine, hyaluronic acid and the like.

Pharmaceutical compositions of the invention can also comprise conventional pharmaceutical excipients and/or additives. Suitable pharmaceutical excipients include stabilizers, antioxidants, osmolality adjusting agents, buffers, and pH adjusting agents. Suitable additives include physiologically biocompatible buffers (e.g., tromethamine hydrochloride), additions of chelants (such as, for example, DTPA or DTPA-bisamide) or calcium chelate complexes (as for example calcium DTPA, CaNaDTPA-bisamide), or, optionally, additions of calcium or sodium salts (for example, calcium chloride, calcium ascorbate, calcium gluconate or calcium lactate). Pharmaceutical compositions of the invention can be packaged for use in liquid form, or can be lyophilized.

For solid compositions, conventional non-toxic solid carriers can be used; for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like.

For example, a solid pharmaceutical composition for oral administration can comprise any of the carriers and excipients listed above and 10-95%, preferably 25%-75%, of one or more iRNA agents of the invention.

By “pharmaceutically acceptable formulation” is meant a composition or formulation that allows for the effective distribution of the nucleic acid molecules of the instant invention in the physical location most suitable for their desired activity. Non-limiting examples of agents suitable for formulation with the nucleic acid molecules of the instant invention include: P-glycoprotein inhibitors (such as PluronicP85), which can enhance entry of drugs into the CNS (Jolliet-Riant and Tillement, Fundam. Clin. Pharmacol. 13:16, 1999); biodegradable polymers, such as poly (DL-lactide-coglycolide) microspheres for sustained release delivery. Other non-limiting examples of delivery strategies for the nucleic acid molecules of the instant invention include material described in Boado et al., J. Pharm. Sci. 87:1308, 1998; Tyler et al., FEBS Lett. 421:280, 1999; Pardridge et al., PNAS USA. 92:5592, 1995; Boado, Adv. Drug Delivery Rev. 15:73, 1995; Aldrian-Herrada et al., Nucleic Acids Res. 26:4910, 1998; and Tyler et al., PNAS USA 96:7053, 1999.

The invention also features the use of the composition comprising surface-modified liposomes containing poly (ethylene glycol) lipids (PEG-modified, or long-circulating liposomes or stealth liposomes). These formulations offer a method for increasing the accumulation of drugs in target tissues. This class of drug carriers resists opsonization and elimination by the mononuclear phagocytic system (WPS or RES), thereby enabling longer blood circulation times and enhanced tissue exposure for the encapsulated drug (Lasic et al., Chem. Rev. 95:2601, 1995; Ishiwata et al., Chem.Phare. Bull. 43:1005, 1995).

Such liposomes have been shown to accumulate selectively in tumors, presumably by extravasation and capture in the neovascularized target tissues (Lasic et al., Science 267:1275, 1995; Oku et al., Biochim. Biophys. Acta 1238:86, 1995). The long-circulating liposomes enhance the pharmacokinetics and pharmacodynamics of DNA and RNA, particularly compared to conventional cationic liposomes which are known to accumulate in tissues of the MPS (Liu et al., J. Biol. Chem. 42:24864, 1995; Choi et al., International PCT Publication No. WO 96/10391; Ansell et al., International PCT Publication No. WO 96/10390; Holland et al., International PCT Publication No. WO 96/10392). Long-circulating liposomes are also likely to protect drugs from nuclease degradation to a greater extent compared to cationic liposomes, based on their ability to avoid accumulation in metabolically aggressive MPS tissues such as the liver and spleen.

Alternatively, certain iRNA agents of the instant invention can be expressed within cells from eukaryotic promoters (e.g., Izant and Weintraub, Science 229:345, 1985; McGarry and Lindquist, Proc. Natl. Acad. Sci. USA 83:399, 1986; Scanlon et al., Proc.Natl. Acad. Sci. USA 88:10591, 1991; Kashani-Sabet et al., Antisense Res. Dev. 2:3, 1992; Dropulic et al., J. Virol. 66:1432, 1992; Weerasinghe et al., J. Virol. 65:5531, 1991; Ojwanget al., Proc. Natl. Acad. Sci. USA 89:10802, 1992; Chen et al., Nucleic Acids Res. 20:4581, 1992; Sarver et al., Science 247:1222, 1990; Thompson et al., Nucleic Acids Res. 23:2259, 1995; Good et al., Gene Therapy 4:45, 1997). Those skilled in the art realize that any nucleic acid can be expressed in eukaryotic cells from the appropriate DNA/RNA vector. The activity of such nucleic acids can be augmented by their release from the primary transcript by a enzymatic nucleic acid (Draper et al., PCT WO 93/23569, and Sullivan et al., PCT WO 94/02595; Ohkawa et al., Nucleic Acids Symp. Ser. 27:156, 1992; Taira et al., Nucleic Acids Res. 19:5125, 1991; Ventura et al., Nucleic Acids Res. 21:3249, 1993; Chowrira et al., J. Biol. Chem. 269:25856, 1994).

In another aspect of the invention, RNA molecules of the present invention can be expressed from transcription units (see for example Couture et al., Trends in Genetics 12:510, 1996) inserted into DNA or RNA vectors. The recombinant vectors can be DNA plasmids or viral vectors. iRNA agent-expressing viral vectors can be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. In another embodiment, pol III based constructs are used to express nucleic acid molecules of the invention (see for example Thompson, U.S. Pats. Nos. 5,902,880 and 6,146,886). The recombinant vectors capable of expressing the iRNA agents can be delivered as described above, and persist in target cells. Alternatively, viral vectors can be used that provide for transient expression of nucleic acid molecules. Such vectors can be repeatedly administered as necessary. Once expressed, the iRNA agent interacts with the target mRNA and generates an RNAi response. Delivery of iRNA agent-expressing vectors can be systemic, such as by intravenous or intramuscular administration, by administration to target cells ex-planted from a subject followed by reintroduction into the subject, or by any other means that would allow for introduction into the desired target cell (for a review see Couture et al., Trends in Genetics 12:510, 1996).

The present invention also includes compositions prepared for storage or administration that include a pharmaceutically effective amount of the desired compounds in a pharmaceutically acceptable carrier. The term “pharmaceutically acceptable carrier” means that the carrier can be taken into the subject with no significant adverse toxicological effects on the subject. Acceptable carriers for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985), hereby incorporated by reference herein. The term is intended to include any and all solvents, dispersion media, coatings, preservatives, e.g. antibacterial and antifungal agents, isotonic and absorption delaying agents, stabilizers, antioxidants, suspending agents, dyes, flavoring agents, and the like, compatible with pharmaceutical administration. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

The types of pharmaceutical excipients that are useful as carrier include stabilizers such as human serum albumin (HSA), bulking agents such as carbohydrates, amino acids and polypeptides; pH adjusters or buffers; salts such as sodium chloride; and the like. These carriers may be in a crystalline or amorphous form or may be a mixture of the two.

Preservatives include, for example, without limitation, sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid.

Bulking agents that are particularly valuable include compatible carbohydrates, polypeptides, amino acids or combinations thereof. Suitable carbohydrates include monosaccharides such as galactose, D-mannose, sorbose, and the like; disaccharides, such as lactose, trehalose, and the like; cyclodextrins, such as 2-hydroxypropyl-beta-cyclodextrin; and polysaccharides, such as raffmose, maltodextrins, dextrans, and the like; alditols, such as mannitol, xylitol, and the like. A preferred group of carbohydrates includes lactose, threhalose, raffinose maltodextrins, and mannitol. Suitable polypeptides include aspartame. Amino acids include alanine and glycine, with glycine being preferred.

Suitable pH adjusters or buffers include organic salts prepared from organic acids and bases, such as sodium citrate, sodium ascorbate, and the like; sodium citrate is preferred.

Treatment Methods and Delivery

Administration of the iRNA Agents A patient who has been diagnosed with a disorder characterized by undesired TGF-beta signaling can be treated by administration of an iRNA agent described herein to block the negative effects of TGF-beta, thereby alleviating the symptoms associated with undesired TGF-beta signaling. For example, the iRNA agent can alleviate symptoms associated with a disease of the lung, such as a fibrotic disorder. In other examples, the iRNA agent can be administered to treat a patient who has a fibrotic or sclerotic disease of the kidney or liver; a fibroproliferative cardiovascular disease; a collagen vascular disorder; or any other fibroproliferative disorder associated with undesired TGF-beta signaling.

A composition that includes an iRNA agent of the present invention, e.g., an iRNA agent that targets TGF-beta, can be delivered to a subject by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated. In general, the delivery of the iRNA agents of the present invention is done to achieve delivery into the subject to the site of undesired TGF-beta signaling. The preferred means of administering the iRNA agents of the present invention is through either a local administration to the site of fibrosis or sclerosis, such as the lung, e.g. by inhalation, or systemically through enteral or parenteral administration.

Suitable enteral administration routes include oral delivery.

Suitable parenteral administration routes include intravascular administration (e.g., intravenous bolus injection, intravenous infusion, intra-arterial bolus injection, intra-arterial infusion and catheter instillation into the vasculature); peri- and intra-tissue injection; subcutaneous injection, deposition including subcutaneous infusion (such as by osmotic pumps), or transdermal application; intraperitoneal or intramuscular injection; intrathecal or intraventricular administration; intraocular, intraotic, intranasal, or intrapulmonary administration; or direct application to the area at or near the site of undesired TGF-beta signaling, for example by a catheter or other placement device (e.g., a pellet or implant comprising a porous, non-porous, or gelatinous material). It is preferred that injections or infusions of the iRNA agent be given at or near the site of undesired TGF-beta signaling.

The anti-TGF-beta iRNA agents can be administered systemically, e.g., orally or by intramuscular injection or by intravenous injection, in admixture with a pharmaceutically acceptable carrier adapted for the route of administration. Methods for the delivery of nucleic acid molecules are described in Akhtar et al., Trends in Cell Bio. 2:139, 1992; Delivery Strategies for Antisense Oligonucleotide Therapeutics, ed. Akhtar, 1995; Maurer et al., Mol. Membr. Biol., 16:129, 1999; Hofland and Huang, Handb. Exp. Pharmacol. 137:165, 1999; and Lee et al., ACS Symp. Ser. 752:184, 2000, all of which are incorporated herein by reference. Beigelman et al., U.S. Pat. No. 6,395,713 and Sullivan et al., PCT WO 94/02595 further describe the general methods for delivery of nucleic acid molecules. Nucleic acid molecules can be administered to cells by a variety of methods known to those of skill in the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins (see for example Gonzalez et al., Bioconjugate Chem. 10:1068, 1999), biodegradable nanocapsules, and bioadhesive microspheres, or by proteinaceous vectors (O'Hare and Normand, International PCT Publication No. WO 00/53722).

Another aspect of the invention provides for the delivery of iRNA agents to the respiratory tract. The respiratory tract includes the upper airways, including the oropharynx and larynx, followed by the lower airways, which include the trachea followed by bifurcations into the bronchi and bronchioli. The upper and lower airways are called the conductive airways. The terminal bronchioli then divide into respiratory bronchioli which then lead to the ultimate respiratory zone, the alveoli, or deep lung. The deep lung, or alveoli, are the primary target of inhaled therapeutic aerosols for systemic delivery of iRNA agents.

Pulmonary delivery compositions can be delivered by inhalation by the patient of a dispersion so that the composition, preferably the iRNA agent, within the dispersion can reach the lung where it can, for example, be readily absorbed through the alveolar region directly into blood circulation. Pulmonary delivery can be effective both for systemic delivery and for localized delivery to treat diseases of the lungs.

Pulmonary delivery can be achieved by different approaches, including the use of nebulized, aerosolized, micellular and dry powder-based formulations; administration by inhalation may be oral and/or nasal. Delivery can be achieved with liquid nebulizers, aerosol-based inhalers, and dry powder dispersion devices. Metered-dose devices are preferred. One of the benefits of using an atomizer or inhaler is that the potential for contamination is minimized because the devices are self contained. Dry powder dispersion devices, for example, deliver drugs that may be readily formulated as dry powders. An iRNA composition may be stably stored as lyophilized or spray-dried powders by itself or in combination with suitable powder carriers. The delivery of a composition for inhalation can be mediated by a dosing timing element which can include a timer, a dose counter, time measuring device, or a time indicator which when incorporated into the device enables dose tracking, compliance monitoring, and/or dose triggering to a patient during administration of the aerosol medicament.

Examples of pharmaceutical devices for aerosol delivery include metered dose inhalers (MDIs), dry powder inhalers (DPIs), and air-jet nebulizers. Exemplary delivery systems by inhalation which can be readily adapted for delivery of the subject iRNA agents are described in, for example, U.S. Pat. Nos. 5,756,353; 5,858,784; and PCT applications WO98/31346; WO98/10796; WO00/27359; WO01/54664; WO02/060412. Other aerosol formulations that may be used for delivering the iRNA agents are described in U.S. Pat. Nos. 6,294,153; 6,344,194; 6,071,497, and PCT applications WO02/066078; WO02/053190; WO01/60420; WO00/66206. Further, methods for delivering iRNA agents can be adapted from those used in delivering other oligonucleotides (e.g., an antisense oligonucleotide) by inhalation, such as described in Templin et al., Antisense Nucleic Acid Drug Dev, 2000, 10:359-68; Sandrasagra et al., Expert Opin Biol Ther, 2001, 1:979-83; Sandrasagra et al., Antisense Nucleic Acid Drug Dev, 2002, 12:177-81.

The delivery of the inventive agents may also involve the administration of so called “pro-drugs”, i.e. formulations or chemical modifications of a therapeutic substance that require some form of processing or transport by systems innate to the subject organism to release the therapeutic substance, preferably at the site where its action is desired. For example, the human lungs can remove or rapidly degrade hydrolytically cleavable deposited aerosols over periods ranging from minutes to hours. In the upper airways, ciliated epithelia contribute to the “mucociliary excalator” by which particles are swept from the airways toward the mouth. Pavia, D., “Lung Mucociliary Clearance,” in Aerosols and the Lung: Clinical and Experimental Aspects, Clarke, S. W. and Pavia, D., Eds., Butterworths, London, 1984. In the deep lungs, alveolar macrophages are capable of phagocytosing particles soon after their deposition. Warheit et al. Microscopy Res. Tech., 26: 412-422 (1993); and Brain, J. D., “Physiology and Pathophysiology of Pulmonary Macrophages,” in The Reticuloendothelial System, S. M. Reichard and J. Filkins, Eds., Plenum, New. York., pp. 315-327, 1985.

In preferred embodiments, particularly where systemic dosing with the iRNA agent is desired, the aerosoled iRNA agents are formulated as microparticles. Microparticles having a diameter of between 0.5 and ten microns can penetrate the lungs, passing through most of the natural barriers. A diameter of less than ten microns is required to bypass the throat; a diameter of 0.5 microns or greater is required to avoid being exhaled.

The iRNA agent of the invention can be delivered using an implant. Such implants can be biodegradable and/or biocompatible implants, or may be non-biodegradable implants. The implants may be permeable or impermeable to the active agent.

The iRNA agent of the invention can also be administered topically, e.g. to the skin, for example by patch or by direct application to the dermis, or by iontophoresis. Ointments, sprays, or droppable liquids can be delivered by delivery systems known in the art such as applicators or droppers.

The iRNA agent of the invention may be provided in sustained release compositions, such as those described in, for example, U.S. Pat. Nos. 5,672,659 and 5,595,760. The use of immediate or sustained release compositions depends on the nature of the condition being treated. If the condition consists of an acute or over-acute disorder, treatment with an immediate release form will be preferred over a prolonged release composition. Alternatively, for certain preventative or long-term treatments, a sustained release composition may be appropriate.

In addition to treating pre-existing disorders or diseases associated with undesired TGF-beta signaling, iRNA agents of the invention can be administered prophylactically in order to prevent or slow the onset of these and related disorders or diseases. In prophylactic applications, an iRNA of the invention is administered to a patient susceptible to or otherwise at risk of a particular disorder or disease associated with undesired TGF-beta signaling.

The iRNA agent of the invention can be administered in a single dose or in multiple doses. Where the administration of the iRNA agent of the invention is by infusion, the infusion can be a single sustained dose or can be delivered by multiple infusions. Injection of the agent directly into the tissue is at or near the site of undesired TGF-beta signaling is preferred. Multiple injections of the agent into the tissue at or near the site of undesired TGF-beta signaling are also preferred.

Dosage. The dosage can be an amount effective to treat or prevent a disorder or disease associated with undesired TGF-beta signaling.

One skilled in the art can readily determine an appropriate dosage regimen for administering the iRNA agent of the invention to a given subject. For example, the iRNA agent can be administered to the subject once, e.g., as a single injection or deposition at or near the site of undesired TGF-beta signaling. Alternatively, the unit dose is administered less frequently than once a day, e.g., less than every 2, 4, 8 or 30 days. In another embodiment, the unit dose is not administered with a frequency (e.g., not a regular frequency). Because iRNA agent mediated silencing can persist for several days after administering the iRNA agent composition, in many instances, it is possible to administer the composition with a frequency of less than once per day, or, for some instances, only once for the entire therapeutic regimen, or only upon the reoccurrence of a symptom or disease state. Alternatively, the iRNA agent can be administered once or twice daily to a subject for a period of from about three to about twenty-eight days, more preferably from about seven to about ten days. In a preferred dosage regimen, the iRNA agent is injected at or near a site of unwanted TGF-beta expression (such as near a site of fibrosis or sclerosis) once a day for seven days. Where a dosage regimen comprises multiple administrations, it is understood that the effective amount of iRNA agent administered to the subject can comprise the total amount of iRNA agent administered over the entire dosage regimen.

In one embodiment, a subject is administered an initial dose, and one or more maintenance doses of an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent, (e.g., a precursor, e.g., a larger iRNA agent which can be processed into an siRNA agent, or a DNA which encodes an iRNA agent, e.g., a double-stranded iRNA agent, or siRNA agent, or precursor thereof). The maintenance doses are preferably administered no more than once every 5, 10, or 30 days. Further, the treatment regimen may last for a period of time which will vary depending upon the nature of the particular disease, its severity and the overall condition of the patient. In preferred embodiments the dosage may be delivered no more than once per day, e.g., no more than once per 24, 36, 48, or more hours, e.g., no more than once every 5 or 8 days. Following treatment, the patient can be monitored for changes in his condition and for alleviation of the symptoms of the disease state. The dosage of the compound may either be increased in the event the patient does not respond significantly to current dosage levels, or the dose may be decreased if an alleviation of the symptoms of the disease state is observed, if the disease state has been ablated, or if undesired side-effects are observed.

The effective dose can be administered in a single dose or in two or more doses, as desired or considered appropriate under the specific circumstances. If desired to facilitate repeated or frequent infusions, implantation of a delivery device, e.g., a pump, semi-permanent stent (e.g., intravenous, intraperitoneal, intracistemal or intracapsular), or reservoir may be advisable.

The concentration of the iRNA agent composition is an amount sufficient to be effective in treating or preventing a disorder or to regulate a physiological condition in humans. The concentration or amount of iRNA agent administered will depend on the parameters determined for the agent and the method of administration, e.g. administration to the lung. For example, inhalable formulations may require lower concentrations of some ingredients in order to avoid irritation or discomfort compared to oral formulations. It is sometimes desirable to dilute an oral formulation up to 10-100 times in order to provide a suitable inhalable formulation.

Certain factors may influence the dosage required to effectively treat a subject, including but not limited to the severity and responsiveness of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. It will also be appreciated that the effective dosage of an iRNA agent such as an siRNA agent used for treatment may increase or decrease over the course of a particular treatment. Changes in dosage may result and become apparent from the results of diagnostic assays. For example, the subject can be monitored after administering an iRNA agent composition. Based on information from the monitoring, an additional amount of the iRNA agent composition can be administered.

Moreover, depending on the above factors, the course of treatment may last from several days to several months, or until a cure is effected or a diminution of disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual compounds, and can generally be estimated based on EC50s found to be effective in in vitro and in vivo animal models.

Dosage levels on the order of about 1 μg/kg to 100 mg/kg of body weight per administration are useful in the treatment of the disorders or diseases associated with undesired TGF-beta signaling. The preferred dosage range is about 0.00001 mg to about 3 mg per kg body weight of the subject to be treated, or preferably about 0.0001-0.001 mg per kg body weight, about 0.03- 3.0 mg per kg body weight, about 0.1-3.0 mg per kg body weight or about 0.3-3.0 mg per kg body weight.

An iRNA agent can be administered at a unit dose less than about 75 mg per kg of bodyweight, or less than about 70, 60, 50, 40, 30, 20, 10, 5, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, or 0.0005 mg per kg of bodyweight, and less than 200 nmol of iRNA agent (e.g., about 4.4×10¹⁶ copies) per kg ofbodyweight, or less than 1500, 750, 300, 150, 75, 15, 7.5, 1.5, 0.75, 0.15, 0.075, 0.015, 0.0075, 0.0015, 0.00075, 0.00015 nmol of iRNA agent per kg of bodyweight. The unit dose, for example, can be administered by injection (e.g., intravenous or intramuscular, intrathecally, or directly into an organ), an inhaled dose, or a topical application.

Delivery of an iRNA agent directly to an organ (e.g., directly to the liver or lung) can be at a dosage on the order of about 0.00001 mg to about 3 mg per organ, or preferably about 0.0001-0.001 mg per organ, about 0.03- 3.0 mg per organ, about 0.1-3.0 mg per kg body weight or about 0.3-3.0 mg per organ.

Where an initial dose/maintenance dose regimen is followed, the maintenance dose or doses are generally lower than the initial dose, e.g., one-half less of the initial dose. A maintenance regimen can include treating the subject with a dose or doses ranging from 0.01 μg to 75 mg/kg of body weight per day, e.g., 70, 60, 50, 40, 30, 20, 10, 5, 2, 1, 0.5, 0.1, 0.05, 0.01, 0.005, 0.001, or 0.0005 mg per kg of bodyweight per day.

The invention is further illustrated by the following examples, which should not be construed as further limiting.

EXAMPLES Example 1 Selection for the Targeting of TGF-Beta by Short Interfering siRNAs

siRNA design was carried out to identify siRNAs targeting human and mouse TGF-beta 1 genes. The siRNA in silico selection resulted in 28 siRNAs satisfying our selection criteria.

Human (NM_(—)000660.3; May 4, 2005) and mouse (NM_(—)011577.1; Dec. 17, 2003) mRNA sequences to TGF-beta were downloaded from NCBI resource http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=nucleotide.

To setup an environment for sequence analysis, BioEdit Sequence Alignment Editor software (Version 7.0.4.1; Hall, T. A., Nucl. Acids. Symp. Ser., 1999, 41:95-98) was downloaded from http://www.mbio.ncsu.edu/BioEdit/bioedit.html and installed on a windows 2000 computer.

The siRNA selection process was run as follows: ClustalW multiple alignment (Thompson J D, et al., Nucleic Acids Res. 1994, 22:4673-80) function of the software was used to generate a global alignment of human and mouse mRNA sequences. Conserved regions were identified by embedded sequence analysis function of the software. For this, conserved regions were defmed as sequence stretches with a minimum length of 19 bases for all aligned sequences containing no internal gaps. In order to have a reference sequence available for positions of conserved stretches and finally siRNA target region coordination, a mapping file with positions of consensus sequence relative to human mRNA sequence was generated by the software and analyzed by a perl script.

The siRNA design web interface at Whitehead Institute for Biomedical Research (http://jura.wi.mit.edu/siRNAext/) was used to identify all candidate siRNAs targeting the conserved regions as well as their predicted off-target hits to human and mouse sequences. For this purpose, candidate siRNAs proposed by the tool were subjected to the software embedded off-target analysis by running the NCBI blast algorithm against the NCBI human and mouse RefSeq database.

Blast results were downloaded and analyzed by a perl script in order to extract an off-target score for each candidate siRNA that was used for siRNA ranking. Final goal for ranking and selection was to prefer siRNAs with high specificity. We defined an off-target score to express off-target potential of each siRNA based on the following assumptions:

1) high specificity can be predicted by weak identity to off-target hits

2) positions 2 to 9 (counting 5′ to 3′) of a strand (seed region) may contribute more to off-target potential than rest of sequence (non-seed region)

Thus, the identity score of the antisense strand calculated by blast was considered as well as the positions of occurring mismatches. The off-target score was defmed as the highest score out of all scores for an siRNA calculated for each off-target hit obtained by blast.

The off-target score was calculated as follows: identity score—0.2 * mismatches in seed region.

siRNAs were sorted according to off-target score (ascending). The top 28 siRNAs according to the above criteria were selected and synthesized.

Designing siRNAs Against TGF-Beta mRNA

siRNA against TGF-beta mRNA were synthesized chemically using procedures established in the art. Two different designs of siRNAs were synthesized and tested for each base sequence obtained in the selection step described above, for a total of 56 siRNAs. The first group consisted of unmodified ribonucleotides, except that the unpaired 3′-overhangs on both strands consisted of 2′-deoxy thymidines. The second group further included a phosphorothioate linkage between the two unpaired 2′-deoxy thymidines at the end of each strand, 2′O-methyl modifications at every pyrimidine base in the sense strand, and 2′O-methyl modifications at every uridine occurring in a sequence context of 5′-ua-3′ and every cytidine occurring in a sequence context of 5′-ca-3′. Modifications in the oligonucleotide strands were accomplished by using the appropriate modified monomer phosphoramidite. The siRNA sequences of those siRNAs synthesized are listed in Table 1, together with the position of the target sequence for each siRNA in NM_(—)000660.3.

Example 2 TGF-Beta siRNA in Vitro Screening Protocol

Human lung epithelial A549 carcinoma cells were transfected with unstabilized and phosphorothioate/O-methyl exo-/endonuclease stabilized siRNAs to select a set of most active siRNAs for further development as potential drug candidates in preclinical and clinical studies.

For transfections, A549 cells (ATCC, Manassas, USA, ATCC #: CCL-185) were seeded at 1.5×10⁴ cells/well on 96-well cell culture plates (Greiner Bio-One GmbH, Frickenhausen, Germany) in 100 μl growth medium (RPMI 1640, 10% fetal calf serum, 100 u/ml penicillin 100 μg/ml streptomycin, 2 mM L-glutamine; Biochrom AG, Berlin, Germany). Transfection of each siRNA was performed 24 h post-seeding at 100 nM and 10 nM fmal concentration of siRNA duplex in quadruplets using Lipofectamine 2000 (Invitrogen GmbH, Karlsruhe, Germany). For each well, 0.5 μl Lipofectamine 2000 were mixed with 12.5 μl Opti-MEM (Invitrogen) and incubated for S min at room temperature. To achieve a fmal siRNA concentration of 100 nNM in the incubation mixture, 2.5 μl of a 5 μM solution of siRNA in annealing buffer per well were mixed with 10 μl Opti-MEM, per well. To achieve a fmal siRNA concentration of 10 nM, 2.5 μl of a 0.5 μM solution of siRNA in annealing buffer were mixed with 10 μl Opti-MEM, per well. The siRNA solution was combined with the diluted Lipofectamine 2000 solution, gently mixed and incubated for 20 minutes at room temperature to allow complex formation. In the meantime, growth medium was removed from cells and replaced by 100 μl/well of fresh medium. 25 μl of the siRNA-Lipofectamine2000-complex solution were applied to the cells to a final volume of 125 μl per well and cells were incubated for 24 h at 37° C. and 5% CO₂ in a humidified incubator (Heraeus GmbH, Hanau).

Following incubation, TGF-beta mRNA levels were determined by QuantiGene bDNA-kit (Genospectra, Fremont, USA). The incubation mixture was replaced by 100 μl fresh growth medium and cells were lysed by applying 50 μl of lysis mixture from the QuantiGene bDNA-kit and incubation for 30 min at 53° C. Cell lysates were incubated in parallel with bDNA probes specific to hGAPDH (10 μl lysate) and hTGF-beta (40 μl lysate) on QuantiGene Capture Plates and processed according to the manufacturer's protocol for the QuantiGene bDNA kit. The nucleotide sequences of the bDNA probes used for hTGF-beta and hGAPDH are given in Table 2 and Table 3 below, respectively. Finally, chemoluminescence was measured in a Victor2-Light (Perkin Elmer, Wiesbaden, Germany) as relative light units (RLU) and values obtained with hGAPDH and hTGF-beta probesets were normalized to the respective GAPDH values for each well. TGF-beta/GAPDH ratios obtained with siRNAs directed against TGF-beta fmally were related to the value obtained with the same concentration (100 nM or 10 nM) of an unspecific siRNA (directed against ApoB) which was set to 100%.

Effective siRNAs from the screen were further characterized by dose response curves (DRC). Transfections for dose response curves were performed at the following concentrations: 100 nM, 25 nM, 6.3 nM, 1.6 nM, 0.4 nM, 0.1 nM, 25 pM according to the above protocol. The % TGF-beta mRNA knockdown again was related to a 100% value obtained from a control siRNA transfection. The dsRNA concentrations at which 50% of their maximal activity was achieved (Inhibitory concentration 50%, IC50) were calculated by curve fitting with the computer software Xlfit, (ID Business Solutions Ltd., Guildford, Surrey, UK) using the following parameters: Dose Response One Site, 4 Parameter Logistic Model, fit=(A+((B−A)/(1+(((10ˆC)/x)ˆD)))), inv=((10ˆC)/((((B−A)/(y−A))−1)ˆ(1/D))), res=(y−fit).

bDNA Probes Used in bDNA Assay for TGF-β (Generated with Bayer QuantiGene Probeset Software): TABLE 2 TGF-β-specific probes detecting hsTGF-β1 (Genbank accession no. NM_000660.3) SEQ FPL Name Function Sequence ID NO hsTGFb 001 CE GGGCTCCGGTTCTGCACTCTTTTT 113 TCTCTTGGAAAGAAAGT hsTGFb 002 CE CGCGGGTGACCTCCTTGGTTTTTC 114 TCTTGGAAAGAAAGT hsTGFb 003 CE GCAGCTCTGCCCGGGAGATTTTTC 115 TCTTGGAAAGAAAGT hsTGFb 004 CE TTTTAACTTGAGCCTCAGCAGACT 116 TTTTCTCTTGGAAAGAAAGT hsTGFb 005 CE GGTTGCTGAGGTATCGCCAGTTTT 117 TCTCTTGGAAAGAAAGT hsTGFb 006 CE GCTGGGTGCCAGCAGCCTTTTTCT 118 CTTGGAAAGAAAGT hsTGFb 007 LE CGTAGTAGTCGGCCTCAGGCTCTT 119 TTTAGGCATAGGACCCGTGTCT hsTGFb 008 LE TGTGGGTTTCCACCATTAGCATTT 120 TTAGGCATAGGACCCGTGTCT hsTGFb 009 LE GCTTCTCGGAGCTCTGATGTGTTT 121 TTTAGGCATAGGACCCGTGTCT hsTGFb 010 LE GCAACACGGGTTCAGGTACCTTTT 122 TAGGCATAGGACCCGTGTCT hsTGFb 011 LE GAATTGTTGCTGTATTTCTGGTAC 123 ATTTTTAGGCATAGGACCCGTGTC T hsTGFb 012 BL TGCTTGAACTTGTCATAGATTTCG 124 T hsTGFb 013 BL TGAAGAACATATATATGCTGTGTG 125 TACTC hsTGFb 014 BL GCTCCACGTGCTGCTCCAC 126

TABLE 3 GAPDH-specific probes detecting hsGAPDH (Genbank accession no. NM_002046.2): SEQ FPL Name Function Sequence ID NO hGAP001 CE GAATTTGCCATGGGTGGAATTTTTTCT 127 CTTGGAAAGAAAGT hGAP002 CE GGAGGGATCTCGCTCCTGGATTTTTCT 128 CTTGGAAAGAAAGT hGAP003 CE CCCCAGCCTTCTCCATGGTTTTTTCTC 129 TTGGAAAGAAAGT hGAP004 CE GCTCCCCCCTGCAAATGAGTTTTTCTC 130 TTGGAAAGAAAGT hGAP005 LE AGCCTTGACGGTGCCATGTTTTTAGGC 131 ATAGGACCCGTGTCT hGAP006 LE GATGACAAGCTTCCCGTTCTCTTTTTA 132 GGCATAGGACCCGTGTCT hGAP007 LE AGATGGTGATGGGATTTCCATTTTTTT 133 AGGCATAGGACCCGTGTCT hGAP008 LE GCATCGCCCCACTTGATTTTTTTTTAG 134 GCATAGGACCCGTGTCT hGAP009 LE CACGACGTACTCAGCGCCATTTTTAGG 135 CATAGGACCCGTGTCT hGAP010 LE GGCAGAGATGATGACCCTTTTGTTTTT 136 AGGCATAGGACCCGTGTCT hGAP011 BL GGTGAAGACGCCAGTGGACTC 137

Table 4 shows the relative activity of the dsRNA duplexes of Table 1 towards reducing TGF-beta mRNA in A549 cells after incubation with the respective dsRNA at 100 nM or 10 nM concentration, expressed as % of the TGF-beta mRNA concentration found in A549 cells that were similarly treated except for incubation with the same concentration of a dsRNA specific for ApoB. In addition, IC50 are given for select duplexes. TABLE 4 Activity of siRNAs in lowering TGF-beta mRNA in A549 cells compared to A549 cells treated with a control siRNA specific for ApoB remaining TGF-beta RNA in % of control at 100 nM at 10 nM Duplex identifier duplex conc. duplex conc. IC(50) [nM] AL-DP-6837 29 ± 5%  47 ± 19% AL-DP-6140 84 ± 7%  88 ± 9%  AL-DP-6838 22 ± 12% 34 ± 8%  0.67 AL-DP-6141 81 ± 16% 118 ± 13%  AL-DP-6839 99 ± 10% 105 ± 5%  AL-DP-6142 87 ± 3%  115 ± 18%  AL-DP-6840 31 ± 6%  37 ± 1%  AL-DP-6143 48 ± 3%  86 ± 7%  23 AL-DP-6841 75 ± 13% 65 ± 29% AL-DP-6144 80 ± 7%  94 ± 12% AL-DP-6842 28 ± 10% 27 ± 4%  0.12 AL-DP-6145 78 ± 9%  100 ± 22%  AL-DP-6843 77 ± 9%  69 ± 13% AL-DP-6146 81 ± 3%  102 ± 4%  AL-DP-6844 48 ± 7%  45 ± 20% AL-DP-6147 71 ± 18% 99 ± 12% AL-DP-6845 20 ± 17% 29 ± 5%  0.16 AL-DP-6148 87 ± 20% 98 ± 11% AL-DP-6846 40 ± 14% 49 ± 29% AL-DP-6149 90 ± 13% 96 ± 13% AL-DP-6847 36 ± 22% 46 ± 27% AL-DP-6150 66 ± 22% 75 ± 9%  AL-DP-6848 14 ± 5%  20 ± 6%  0.31 AL-DP-6151 95 ± 5%  122 ± 20%  AL-DP-6849 33 ± 12% 31 ± 9%  AL-DP-6262 75 ± 5%  113 ± 4%  AL-DP-6850 68 ± 30% 74 ± 6%  AL-DP-6263 102 ± 27%  142 ± 19%  AL-DP-6851 26 ± 11% 52 ± 11% AL-DP-6264 23 ± 3%  59 ± 9%  4.4 AL-DP-6852 21 ± 9%  32 ± 18% AL-DP-6265 86 ± 15% 79 ± 16% AL-DP-6853 41 ± 12% 52 ± 14% AL-DP-6266 83 ± 3%  97 ± 32% AL-DP-6854 92 ± 12% 118 ± 33%  AL-DP-6267 79 ± 12% 83 ± 11% AL-DP-6855 22 ± 2%  28 ± 6%  AL-DP-6268 88 ± 15% 107 ± 46%  AL-DP-6856 43 ± 4%  54 ± 3%  AL-DP-6269 70 ± 11% 92 ± 24% AL-DP-6857 13 ± 5%  35 ± 24% 0.04 AL-DP-6270 71 ± 15% 89 ± 30% AL-DP-6858 11 ± 3%  28 ± 17% 0.13 AL-DP-6271 34 ± 12% 51 ± 15% 0.68 AL-DP-6859 14 ± 2%  26 ± 11% 0.15 AL-DP-6272 33 ± 5%  56 ± 6%  2.2 AL-DP-6860 31 ± 1%  45 ± 11% AL-DP-6273 118 ± 29%  161 ± 17%  AL-DP-6861 32 ± 7%  65 ± 37% AL-DP-6274 76 ± 4%  111 ± 11%  AL-DP-6862 16 ± 3%  27 ± 14% 0.19 AL-DP-6275 93 ± 41% 96 ± 20% AL-DP-6863 36 ± 17% 37 ± 15% AL-DP-6276 56 ± 12% 74 ± 32% AL-DP-6864 46 ± 26% 62 ± 19% AL-DP-6277 110 ± 18%  83 ± 40%

From Table 4, it can be seen that, at 100 nM concentration, AL-DP-6858, AL-DP-6857, AL-DP-6859, AL-DP-6848, and AL-DP-6862 reduced TGF-beta mRNA in A549 cells by more than 80%. Additionally, under these circumstances, AL-DP-6845, AL-DP-6852, AL-DP-6838, AL-DP-6855, AL-DP-6264, AL-DP-6851, AL-DP-6842, and AL-DP-6837 reduced TGF-beta mRNA in A549 cells by more than 70%. Additionally, AL-DP-6840, AL-DP-6860, AL-DP-6861, AL-DP-6849, AL-DP-6272, AL-DP-6271, AL-DP-6847, AL-DP-6863 reduced TGF-beta mRNA in A549 cells by more than 60%. Additionally, AL-DP-6846, AL-DP-6853, AL-DP-6856, AL-DP-6864, AL-DP-6844, AL-DP-6143 reduced TGF-beta mRNA in A549 cells by more than 50%. Additionally, AL-DP-6276 reduced TGF-beta mRNA in A549 cells by more than 40%. Additionally, AL-DP-6150 and AL-DP-6850 reduced TGF-beta mRNA in A549 cells by more than 30%. Finally, AL-DP-6269, AL-DP-6270, AL-DP-6147, AL-DP-6262, AL-DP-6841, AL-DP-6274, AL-DP-6843, AL-DP-6145, and AL-DP-6267 reduced TGF-beta mRNA in A549 cells by more than 20%.

Example 3 Screening of Additional siRNA for Activity in Inhibiting TGF-Beta Expression

In order to identify as many RNAi agents with suitable activity as possible, the above screen was extended to further target sequences. For the selection of an expanded screening set we re-calculated the predicted specificity based on the newly available human RefSeq database (Human mRNA sequences in RefSeq release version 21 (downloaded Jan. 12, 2007)) and selected only those 220 non-poly-G siRNAs (no occurrence of 3 or more consecutive guanosines) targeting 19mer target sequences in NM_(—)000660.3 with off-target scores of 3 or more for the antisense strand. These agents were then screened for their activity in lowering the amount of TGF-beta mRNA present in A549 cells treated with the agents as described above, except that transfection with the agents was performed directly after seeding, rather than 24h after seeding, and that the concentration of the agents in the transfection mixture was 30 nM.

As may be concluded from the results shown in Table 5, AD-14501, AD-14503, AD-14507, AD- 14554, AD-14594, AD-14597, and AD- 14633 reduced TGF-beta mRNA in A549 cells by more than 90%. Additionally, under these circumstances, AD-14419, AD-1 4420, AD-14421, AD-14422, AD-14423, AD-14428, AD-14430, AD-14434, AD-14438, AD-14449, AD-14453, AD-14459, AD-14460, AD-14464, AD-14469, AD-14470, AD-14473, AD-14474, AD-14476, AD-14486, AD-14490, AD-14495, AD-14496, AD-14497, AD-14509, AD-14515, AD-14522, AD-14526, AD-14540, AD-14552, AD-14555, AD-14557, AD-14565, AD-14567, AD-14568, AD-14582, AD-14588, AD-14590, AD-14592, AD-14598, AD-14600, AD-14601, AD-14603, AD-14604, AD-14608, AD-14610, AD-14612, AD-14614, AD-14622, AD-14634, and AD-14635 reduced TGF-beta mRNA in A549 cells by more than 80%. Additionally, under these circumstances, AD-14425, AD-14426, AD-14427, AD-14429, AD-14431, AD-14436, AD-14437, AD-14441, AD-14448, AD-14458, AD-14463, AD-14467, AD-14477, AD-14482, AD-14483, AD-14491, AD-14502, AD-14505, AD-14508, AD-14512, AD-14513, AD-14519, AD-14524, AD-14537, AD-14546, AD-14548, AD-14549, AD-14559, AD-14563, AD-14564, AD-14569, AD-14578, AD-14579, AD-14587, AD-14595, AD-14599, AD-14607, AD-14609, AD-14629, AD-14631, and AD-14637 reduced TGF-beta mRNA in A549 cells by more than 70%. Additionally, under these circumstances, AD-1 4447, AD-14451, AD-14471, AD-14484, AD-14487, AD-14498, AD-14523, AD-14527, AD-14529, AD-14539, AD-14541, AD-14558, AD-14561, AD-14573, AD-14589, AD-14596, AD-14605, AD-14615, AD-14626, and AD-14630 reduced TGF-beta mRNA in A549 cells by more than 60%. Additionally, under these circumstances, AD-14432, AD-14480, AD-14485, AD-14488, AD-14499, AD-14504, AD-14516, AD-14518, AD-14520, AD-14547, AD-14572, AD-14577, AD-14580, AD-14583, AD-14584, AD-14618, AD-14621, and AD-14625 reduced TGF-beta mRNA in A549 cells by more than 50%. Additionally, under these circumstances, AD-14435, AD-14445, AD-14450, AD-14456, AD-14466, AD-14475, AD-14489, AD-14492, AD-14511, AD-14535, AD-14536, AD-14538, AD-14553, AD-14560, AD-14562, AD-14576, AD-14581, AD-14586, and AD-14627 reduced TGF-beta mRNA in A549 cells by more than 40%. Additionally, under these circumstances, AD-14433, AD-14472, AD-14478, AD-14493, AD-14510, AD-14544, AD-14566, AD-14570, AD-14575, AD-14593, and AD-14613 reduced TGF-beta mRNA in A549 cells by more than 30%. Additionally, under these circumstances, AD-14424, AD-14442, AD-14444, AD-14446, AD-14454, AD-14525, AD-14543, AD-14571, AD-14606, AD-14611, AD-14616, AD-14617, AD-14619, and AD-14638 reduced TGF-beta mRNA in A549 cells by more than 20%. TABLE 5 Additional RNAi agents targeting hTGF-beta Remaining TGF-beta mRNA target SEQ SEQ in % of Duplex 19 mer target sequence in ID Antisense strand ID controls ± identifier sequence NM_000660.3 Sense strand sequence NO: sequence NO: stand. dev. AD-14419 aauuccuggcgauaccuca 1396-1414 aauuccuggcgauaccucaTT 138 ugagguaucgccaggaauuTT 139 16 ± 1 AD-14420 ucgcgcccaucuagguuau 654-672 ucgcgcccaucuagguuauTT 140 auaaccuagaugggcgcgaTT 141 19 ± 2 AD-14421 ggucacccgcgugcuaaug 1188-1206 ggucacccgcgugcuaaugTT 142 cauuagcacgcgggugaccTT 143 19 ± 2 AD-14422 aggucacccgcgugcuaau 1187-1205 aggucacccgcgugcuaauTT 144 auuagcacgcgggugaccuTT 145 10 ± 1 AD-14423 cacccgcgugcuaauggug 1191-1209 cacccgcgugcuaauggugTT 146 caccauuagcacgcgggugTT 147 18 ± 1 AD-14424 uacaaccagcauaacccgg 1894-1912 uacaaccagcauaacccggTT 148 ccggguuaugcugguuguaTT 149 79 ± 5 AD-14425 aucgcgcccaucuagguua 653-671 aucgcgcccaucuagguuaTT 150 uaaccuagaugggcgcgauTT 151 24 ± 1 AD-14426 guaccagaucgcgcccauc 646-664 guaccagaucgcgcccaucTT 152 gaugggcgcgaucugguacTT 153 21 ± 1 AD-14427 agacggaucucucuccgac 589-607 agacggaucucucuccgacTT 154 gucggagagagauccgucuTT 155 26 ± 4 AD-14428 cgcgcccaucuagguuauu 655-673 cgcgcccaucuagguuauuTT 156 aauaaccuagaugggcgcgTT 157 19 ± 1 AD-14429 cccgcgcauccuagacccu 558-576 cccgcgcauccuagacccuTT 158 agggucuaggaugcgcgggTT 159 24 ± 3 AD-14430 gcgcccaucuagguuauuu 656-674 gcgcccaucuagguuauuuTT 160 aaauaaccuagaugggcgcTT 161 18 ± 1 AD-14431 uccgugggauacugagaca 674-692 uccgugggauacugagacaTT 162 ugucucaguaucccacggaTT 163 25 ± 3 AD-14432 cuuucgccuuagcgcccac 1515-1533 cuuucgccuuagcgcccacTT 164 gugggcgcuaaggcgaaagTT 165 41 ± 2 AD-14433 acccgcgugcuaauggugg 1192-1210 acccgcgugcuaaugguggTT 166 ccaccauuagcacgcggguTT 167 60 ± 4 AD-14434 gcaacaauuccuggcgaua 1391-1409 gcaacaauuccuggcgauaTT 168 uaucgccaggaauuguugcTT 169 10 ± 0 AD-14435 aacggguucacuaccggcc 1576-1594 aacggguucacuaccggccTT 170 ggccgguagugaacccguuTT 171 57 ± 4 AD-14436 cggguucacuaccggccgc 1578-1596 cggguucacuaccggccgcTT 172 gcggccgguagugaacccgTT 173 28 ± 3 AD-14437 cuguauuuaaggacacccg 2117-2135 cuguauuuaaggacacccgTT 174 cggguguccuuaaauacagTT 175 21 ± 1 AD-14438 agguuauuuccgugggaua 666-684 agguuauuuccgugggauaTT 176 uaucccacggaaauaaccuTT 177 19 ± 1 AD-14439 cccucgggagucgccgacc 458-476 cccucgggagucgccgaccTT 178 ggucggcgacucccgagggTT 179 90 ± 4 AD-14440 ugugcggcagugguugagc 1476-1494 ugugcggcagugguugagcTT 180 gcucaaccacugccgcacaTT 181 375 ± 34 AD-14441 caaccagcauaacccgggc 1896-1914 caaccagcauaacccgggcTT 182 gcccggguuaugcugguugTT 183 28 ± 4 AD-14442 uuuugagacuuuuccguug 281-299 uuuugagacuuuuccguugTT 184 caacggaaaagucucaaaaTT 185 75 ± 2 AD-14443 uuugagacuuuuccguugc 282-300 uuugagacuuuuccguugcTT 186 gcaacggaaaagucucaaaTT 187 98 ± 9 AD-14444 cucuuggcgcgacgcugcc 326-344 cucuuggcgcgacgcugccTT 188 ggcagcgucgcgccaagagTT 189 70 ± 4 AD-14445 ucugguaccagaucgcgcc 642-660 ucugguaccagaucgcgccTT 190 ggcgcgaucugguaccagaTT 191 50 ± 2 AD-14446 acaccagcccuguucgcgc 817-835 acaccagcccuguucgcgcTT 192 gcgcgaacagggcugguguTT 193 71 ± 4 AD-14447 cggccggccgcgggacuau 940-958 cggccggccgcgggacuauTT 194 auagucccgcggccggccgTT 195 38 ± 1 AD-14448 gguaccugaacccguguug 1296-1314 gguaccugaacccguguugTT 196 caacacggguucagguaccTT 197 21 ± 1 AD-14449 guaccugaacccguguugc 1297-1315 guaccugaacccguguugcTT 198 gcaacacggguucagguacTT 199 17 ± 1 AD-14450 auuccuggcgauaccucag 1397-1415 auuccuggcgauaccucagTT 200 cugagguaucgccaggaauTT 201 58 ± 6 AD-14451 auugagggcuuucgccuua 1507-1525 auugagggcuuucgccuuaTT 202 uaaggcgaaagcccucaauTT 203 31 ± 3 AD-14452 acaaccagcauaacccggg 1895-1913 acaaccagcauaacccgggTT 204 cccggguuaugcugguuguTT 205 87 ± 8 AD-14453 uguauuuaaggacacccgu 2118-2136 uguauuuaaggacacccguTT 206 acggguguccuuaaauacaTT 207 16 ± 2 AD-14454 gaggacugcggaucucugu 2174-2192 gaggacugcggaucucuguTT 208 acagagauccgcaguccucTT 209 77 ± 5 AD-14455 gggaacacuacuguaguua 2324-2342 gggaacacuacuguaguuaTT 210 uaacuacaguaguguucccTT 211 86 ± 4 AD-14456 accagcccuguucgcgcuc 819-837 accagcccuguucgcgcucTT 212 gagcgcgaacagggcugguTT 213 59 ± 0 AD-14457 agaggacugcggaucucug 2173-2191 agaggacugcggaucucugTT 214 cagagauccgcaguccucuTT 215 91 ± 3 AD-14458 guacuacgugggccgcaag 1968-1986 guacuacgugggccgcaagTT 216 cuugcggcccacguaguacTT 217 24 ± 1 AD-14499 gaucgcgcccaucuagguu 652-670 gaucgcgcccaucuagguuTT 218 aaccuagaugggcgcgaucTT 219 13 ± 1 AD-14460 aacgaaaucuaugacaagu 1219-1237 aacgaaaucuaugacaaguTT 220 acuugucauagauuucguuTT 221 16 ± 2 AD-14461 uucgccuuagcgcccacug 1517-1535 uucgccuuagcgcccacugTT 222 cagugggcgcuaaggcgaaTT 223 107 ± 6  AD-14462 aucaacggguucacuaccg 1573-1591 aucaacggguucacuaccgTT 224 cgguagugaacccguugauTT 225 107 ± 3  AD-14463 ccgcgcauccuagacccuu 559-577 ccgcgcauccuagacccuuTT 226 aagggucuaggaugcgcggTT 227 24 ± 3 AD-14464 gcgcauccuagacccuuuc 561-579 gcgcauccuagacccuuucTT 228 gaaagggucuaggaugcgcTT 229 15 ± 1 AD-14465 uuucgccuuagcgcccacu 1516-1534 uuucgccuuagcgcccacuTT 230 agugggcgcuaaggcgaaaTT 231 85 ± 6 AD-14466 cugguaccagaucgcgccc 643-661 cugguaccagaucgcgcccTT 232 gggcgcgaucugguaccagTT 233 54 ± 3 AD-14467 cagaucgcgcccaucuagg 650-668 cagaucgcgcccaucuaggTT 234 ccuagaugggcgcgaucugTT 235 25 ± 1 AD-14468 uccuaccuuuugccgggag 763-781 uccuaccuuuugccgggagTT 236 cucccggcaaaagguaggaTT 237 93 ± 5 AD-14469 cccuguucgcgcucucggc 824-842 cccuguucgcgcucucggcTT 238 gccgagagcgcgaacagggTT 235 16 ± 2 AD-14470 ccuguucgcgcucucggca 825-843 ccuguucgcgcucucggcaTT 240 ugccgagagcgcgaacaggTT 241 16 ± 3 AD-14471 cuguucgcgcucucggcag 826-844 cuguucgcgcucucggcagTT 242 cugccgagagcgcgaacagTT 243 32 ± 3 AD-14472 aagacuaucgacauggagc 967-985 aagacuaucgacauggagcTT 244 gcuccaugucgauagucuuTT 245 63 ± 9 AD-14473 cccgcgugcuaauggugga 1193-1211 cccgcgugcuaaugguggaTT 246 uccaccauuagcacgcgggTT 247 12 ± 2 AD-14474 cgugcuaaugguggaaacc 1157-1215 cgugcuaaugguggaaaccTT 248 gguuuccaccauuagcacgTT 249 13 ± 1 AD-14475 ccggaguugugcggcagug 1469-1487 ccggaguugugcggcagugTT 250 cacugccgcacaacuccggTT 251 52 ± 6 AD-14476 gcuuucgccuuagcgccca 1514-1532 gcuuucgccuuagcgcccaTT 252 ugggcgcuaaggcgaaagcTT 253 16 ± 0 AD-14477 agggauaacacacugcaag 1549-1567 agggauaacacacugcaagTT 254 cuugcaguguguuaucccuTT 255 22 ± 1 AD-14478 caucaacggguucacuacc 1572-1590 caucaacggguucacuaccTT 256 gguagugaacccguugaugTT 257 68 ± 1 AD-14479 uuuaaggacacccgugccc 2122-2140 uuuaaggacacccgugcccTT 258 gggcacggguguccuuaaaTT 259 92 ± 5 AD-14480 gacuuuuccguugccgcug 287-305 gacuuuuccguugccgcugTT 260 cagcggcaacggaaaagucTT 261 41 ± 5 AD-14481 uuuuccguugccgcuggga 290-308 uuuuccguugccgcugggaTT 262 ucccagcggcaacggaaaaTT 263 81 ± 3 AD-14482 gggaccucuuggcgcgacg 321-339 gggaccucuuggcgcgacgTT 264 cgucgcgccaagaggucccTT 265 26 ± 1 AD-14483 ggaccucuuggcgcgacgc 322-340 ggaccucuuggcgcgacgcTT 266 gcgucgcgccaagagguccTT 267 28 ± 3 AD-14484 gaccucuuggcgcgacgcu 323-341 gaccucuuggcgcgacgcuTT 268 agcgucgcgccaagaggucTT 269 33 ± 1 AD-14485 ccuacacggcgucccucag 419-437 ccuacacggcgucccucagTT 270 cugagggacgccguguaggTT 271 49 ± 1 AD-14486 cgcgcauccuagacccuuu 560-578 cgcgcauccuagacccuuuTT 272 aaagggucuaggaugcgcgTT 273 15 ± 2 AD-14487 cauccuagacccuuucucc 564-582 cauccuagacccuuucuccTT 274 ggagaaagggucuaggaugTT 275 33 ± 7 AD-14488 ugguaccagaucgcgccca 644-662 ugguaccagaucgcgcccaTT 276 ugggcgcgaucugguaccaTT 277 49 ± 5 AD-14489 uaccagaucgcgcccaucu 647-665 uaccagaucgcgcccaucuTT 278 agaugggcgcgaucugguaTT 279 59 ± 6 AD-14490 agaucgcgcccaucuaggu 651-669 agaucgcgcccaucuagguTT 280 accuagaugggcgcgaucuTT 281 19 ± 3 AD-14491 gcccaucuagguuauuucc 658-676 gcccaucuagguuauuuccTT 282 ggaaauaaccuagaugggcTT 283 25 ± 1 AD-14492 cuaccuuuugccgggagac 765-783 cuaccuuuugccgggagacTT 284 gucucccggcaaaagguagTT 285 55 ± 2 AD-14493 guucgcgcucucggcagug 828-846 guucgcgcucucggcagugTT 286 cacugccgagagcgcgaacTT 287 66 ± 9 AD-14494 uucgcgcucucggcagugc 829-847 uucgcgcucucggcagugcTT 288 gcacugccgagagcgcgaaTT 289 102 ± 12 AD-14495 accugcaagacuaucgaca 961-979 accugcaagacuaucgacaTT 290 ugucgauagucuugcagguTT 291 19 ± 1 AD-14496 cugcaagacuaucgacaug 963-981 cugcaagacuaucgacaugTT 292 caugucgauagucuugcagTT 293 14 ± 1 AD-14497 gcaagacuaucgacaugga 965-983 gcaagacuaucgacauggaTT 294 uccaugucgauagucuugcTT 295 15 ± 1 AD-14498 caagacuaucgacauggag 966-984 caagacuaucgacauggagTT 296 cuccaugucgauagucuugTT 297 37 ± 3 AD-14499 uguacaacagcacccgcga 1106-1124 uguacaacagcacccgcgaTT 298 ucgcgggugcuguuguacaTT 299 42 ± 2 AD-14500 ugaggccgacuacuacgcc 1164-1182 ugaggccgacuacuacgccTT 300 ggcguaguagucggccucaTT 301 122 ± 7  AD-14501 aaacccacaacgaaaucua 1211-1229 aaacccacaacgaaaucuaTT 302 uagauuucguuguggguuuTT 303  9 ± 1 AD-14502 ccacaacgaaaucuaugac 1215-1233 ccacaacgaaaucuaugacTT 304 gucauagauuucguuguggTT 305 24 ± 2 AD-14503 aguacacacagcauauaua 1246-1264 aguacacacagcauauauaTT 306 uauauaugcuguguguacuTT 307  8 ± 0 AD-14504 cgguaccugaacccguguu 1295-1313 cgguaccugaacccguguuTT 308 aacacggguucagguaccgTT 309 45 ± 4 AD-14505 uaccugaacccguguugcu 1298-1316 uaccugaacccguguugcuTT 310 agcaacacggguucagguaTT 311 29 ± 2 AD-14506 cccguguugcucucccggg 1306-1324 cccguguugcucucccgggTT 312 cccgggagagcaacacgggTT 313 107 ± 5  AD-14507 cugcgucugcugaggcuca 1330-1348 cugcgucugcugaggcucaTT 314 ugagccucagcagacgcagTT 315  9 ± 1 AD-14508 aggcucaaguuaaaagugg 1342-1360 aggcucaaguuaaaaguggTT 316 ccacuuuuaacuugagccuTT 317 20 ± 1 AD-14509 caacaauuccuggcgauac 1392-1410 caacaauuccuggcgauacTT 318 guaucgccaggaauuguugTT 319 14 ± 1 AD-14510 aacaauuccuggcgauacc 1393-1411 aacaauuccuggcgauaccTT 320 gguaucgccaggaauuguuTT 321 65 ± 3 AD-14511 uggcgauaccucagcaacc 1402-1420 uggcgauaccucagcaaccTT 322 gguugcugagguaucgccaTT 323 58 ± 5 AD-14512 cgauaccucagcaaccggc 1405-1423 cgauaccucagcaaccggcTT 324 gccgguugcugagguaucgTT 32S 20 ± 0 AD-14513 gauaccucagcaaccggcu 1406-1424 gauaccucagcaaccggcuTT 326 agccgguugcugagguaucTT 327 24 ± 1 AD-14514 cuggcacccagcgacucgc 1426-1444 cuggcacccagcgacucgcTT 328 gcgagucgcugggugccagTT 329  86 ± 13 AD-14515 gacucgccagagugguuau 1438-1456 gacucgccagagugguuautT 330 auaaccacucuggcgagucTT 331 11 ± 1 AD-14516 acucgccagagugguuauc 1439-1457 acucgccagagugguuaucTT 332 gauaaccacucuggcgaguTT 333 47 ± 2 AD-14517 ugucaccggaguugugcgg 1464-1482 ugucaccggaguugugcggTT 334 ccgcacaacuccggugacaTT 335 115 ± 7  AD-14518 caccggaguugugcggcag 1467-1485 caccggaguugugcggcagTT 336 cugccgcacaacuccggugTT 337 44 ± 3 AD-14519 accggaguugugcggcagu 1468-1486 accggaguugugcggcaguTT 338 acugccgcacaacuccgguTT 339 28 ± 2 AD-14520 aaauugagggcuuucgccu 1505-1523 aaauugagggcuuucgccuTT 340 aggcgaaagcccucaauuuTT 341 46 ± 2 AD-14521 uugagggcuuucgccuuag 1508-1526 uugagggcuuucgccuuagTT 342 cuaaggcgaaagcccucaaTT 343 130 ± 15 AD-14522 gggcuuucgccuuagcgcc 1512-1530 gggcuuucgccuuagcgccTT 344 ggcgcuaaggcgaaagcccTT 345 14 ± 1 AD-14523 ccuuagcgcccacugcucc 1521-1539 ccuuagcgcccacugcuccTT 346 ggagcagugggcgcuaaggTT 347 30 ± 1 AD-14524 aaguggacaucaacggguu 1565-1583 aaguggacaucaacggguuTT 348 aacccguugauguccacuuTT 349 20 ± 1 AD-14525 caacggguucacuaccggc 1575-1593 caacggguucacuaccggcTT 350 gccgguagugaacccguugTT 351 73 ± 6 AD-14526 cuaccggccgccgagguga 1586-1604 cuaccggccgccgaggugaTT 352 ucaccucggcggccgguagTT 353 18 ± 1 AD-14527 caucugcaaagcucccggc 1675-1693 caucugcaaagcucccggcTT 354 gccgggagcuuugcagaugTT 355 37 ± 2 AD-14528 cguguacuacgugggccgc 1965-1983 cguguacuacgugggccgcTT 356 gcggcccacguaguacacgTT 357 80 ± 4 AD-14529 caacaugaucgugcgcucc 2007-2025 caacaugaucgugcgcuccTT 358 ggagcgcacgaucauguugTT 359 35 ± 2 AD-14530 cugugucauugggcgccug 2189-2207 cugugucauugggcgccugTl 360 caggcgcccaaugacacagTT 361 89 ± 6 AD-14531 ugccugucugcacuauucc 2273-2291 ugccugucugcacuauuccTT 362 ggaauagugcagacaggcaTT 363 97 ± 4 AD-14532 cacuauuccuuugcccggc 2283-2301 cacuauuccuuugcccggcTT 364 gccgggcaaaggaauagugTT 365 98 ± 8 AD-14533 aacacuacuguaguuagau 2327-2345 aacacuacuguaguuagauTT 366 aucuaacuacaguaguguuTT 367 89 ± 8 AD-14534 acacuacuguaguuagauc 2328-2346 acacuacuguaguuagaucTT 368 gaucuaacuacaguaguguTT 369 80 ± 2 AD-14535 gucugagacgagccgccgc 185-203 gucugagacgagccgccgcTT 370 gcggcggcucgucucagacTT 371 57 ± 4 AD-14536 cccuacacggcgucccuca 418-436 cccuacacggcgucccucaTT 372 ugagggacgccguguagggTT 373 50 ± 4 AD-14537 acggaucucucuccgaccu 591-609 acggaucucucuccgaccuTT 374 aggucggagagagauccguTT 375 23 ± 3 AD-14538 ggccggccgcgggacuauc 941-959 ggccggccgcgggacuaucTT 376 gauagucccgcggccggccTT 377 50 ± 2 AD-14539 cgcggccagauccugucca 1015-1033 cgcggccagauccuguccaTT 378 uggacaggaucuggccgcgTT 379 34 ± 3 AD-14540 ggaaacccacaacgaaauc 1209-1227 ggaaacccacaacgaaaucTT 380 gauuucguuguggguuuccTT 381 11 ± 0 AD-14541 acaauuccuggcgauaccu 1394-1412 acaauuccuggcgauaccuTT 382 agguaucgccaggaauuguTT 383 31 ± 2 AD-14542 agucugagacgagccgccg 184-202 agucugagacgagccgccgTT 384 cggcggcucgucucagacuTT 385 87 ± 1 AD-14543 cacggcgucccucaggcgc 423-441 cacggcgucccucaggcgcTT 386 gcgccugagggacgccgugTT 387 76 ± 3 AD-14544 acggcgucccucaggcgcc 424-442 acggcgucccucaggcgccTT 388 ggcgccugagggacgccguTT 389 68 ± 3 AD-14545 accagcccucgggagucgc 453-471 accagcccucgggagucgcTT 390 gcgacucccgagggcugguTT 391 96 ± 7 AD-14546 gcauccuagacccuuucuc 563-S81 gcauccuagacccuuucucTT 392 gagaaagggucuaggaugcTT 393 22 ± 2 AD-14547 gacggaucucucuccgacc 590-608 gacggaucucucuccgaccTT 394 ggucggagagagauccgucTT 395 43 ± 2 AD-14548 gguaccagaucgcgcccau 645-663 gguaccagaucgcgcccauTT 396 augggcgcgaucugguaccTT 397 27 ± 3 AD-14549 uagguuauuuccgugggau 665-683 uagguuauuuccgugggauTT 398 aucccacggaaauaaccuaTT 399 22 ± 1 AD-14550 accuuuugccgggagaccc 767-785 accuuuugccgggagacccTT 400 gggucucccggcaaaagguTT 401 89 ± 2 AD-14551 ucgcgcucucggcagugcc 830-848 ucgcgcucucggcagugccTT 402 ggcacugccgagagcgcgaTT 403 95 ± 3 AD-14552 uauccaccugcaagacuau 956-974 uauccaccugcaagacuauTT 404 auagucuugcagguggauaTT 405 15 ± 1 AD-14553 ccgcggccagauccugucc 1014-1032 ccgcggccagauccuguccTT 406 ggacaggaucuggccgcggTT 407 53 ± 5 AD-14554 aacccacaacgaaaucuau 1212-1230 aacccacaacgaaaucuauTT 408 auagauuucguuguggguuTT 409  8 ± 1 AD-14555 agcgguaccugaacccgug 1293-1311 agcgguaccugaacccgugTT 410 cacggguucagguaccgcuTT 411 14 ± 2 AD-14556 uggcacccagcgacucgcc 1427-1445 uggcacccagcgacucgccTT 412 ggcgagucgcugggugccaTT 413 88 ± 9 AD-14557 cucgccagagugguuaucu 1440-1458 cucgccagagugguuaucuTT 414 agauaaccacucuggcgagTT 415 18 ± 2 AD-14558 cggcagugguugagccgug 1480-1498 cggcagugguugagccgugTT 416 cacggcucaaccacugccgTT 417 32 ± 2 AD-14559 gugguugagccguggaggg 1485-1503 gugguugagccguggagggTT 418 cccuccacggcucaaccacTT 419 24 ± 1 AD-14560 gagggcuuucgccuuagcg 1510-1528 gagggcuuucgccuuagcgTT 420 cgcuaaggcgaaagcccucTT 421 51 ± 2 AD-14561 agggcuuucgccuuagcgc 1511-1529 agggcuuucgccuuagcgcTT 422 gcgcuaaggcgaaagcccuTT 423 37 ± 1 AD-14562 ggugaccuggccaccauuc 1600-1618 ggugaccuggccaccauucTT 424 gaaugguggccaggucaccTT 425 51 ± 5 AD-14563 accauucauggcaugaacc 1612-1630 accauucauggcaugaaccTT 426 gguucaugccaugaaugguTT 427 29 ± 2 AD-14564 cauggcaugaaccggccuu 1618-1636 cauggcaugaaccggccuuTT 428 aaggccgguucaugccaugTT 429 25 ± 2 AD-14565 ccaacuauugcuucagcuc 1712-1730 ccaacuauugcuucagcucTT 430 gagcugaagcaauaguuggTT 431 11 ± 1 AD-14566 gaacugcugcgugcggcag 1740-1758 gaacugcugcgugcggcagTT 432 cugccgcacgcagcaguucTT 433 62 ± 3 AD-14567 gcccuguacaaccagcaua 1888-1906 gcccuguacaaccagcauaTT 434 uaugcugguuguacagggcTT 435 10 ± 0 AD-14568 cuguacaaccagcauaacc 1891-1909 cuguacaaccagcauaaccTT 436 gguuaugcugguuguacagTT 437 19 ± 0 AD-14569 guacaaccagcauaacccg 1893-1911 guacaaccagcauaacccgTT 438 cggguuaugcugguuguacTT 439 21 ± 1 AD-14570 cuauuccuuugcccggcau 2285-2303 cuauuccuuugcccggcauTT 440 augccgggcaaaggaauagTT 441 65 ± 2 AD-14571 agcggaggaaggagucgcc 143-161 agcggaggaaggagucgccTT 442 ggcgacuccuuccuccgcuTT 443 75 ± 2 AD-14572 ggaggaaggagucgccgag 146-164 ggaggaaggagucgccgagTT 444 cucggcgacuccuuccuccTT 445 43 ± 2 AD-14573 acuuuugagacuuuuccgu 279-297 acuuuugagacuuuuccguTT 446 acggaaaagucucaaaaguTT 447 32 ± 2 AD-14574 uugagacuuuuccguugcc 283-301 uugagacuuuuccguugccTT 448 ggcaacggaaaagucucaaTT 449 96 ± 4 AD-14575 accucuuggcgcgacgcug 324-342 accucuuggcgcgacgcugTT 450 cagcgucgcgccaagagguTT 451 67 ± 3 AD-14576 gacccggccucccgcaaag 473-491 gacccggccucccgcaaagTT 452 cuuugcgggaggccgggucTT 453 54 ± 3 AD-14577 cccggccucccgcaaagac 475-493 cccggccucccgcaaagacTT 454 gucuuugcgggaggccgggTT 455 48 ± 4 AD-14578 cuccuccaggagacggauc 579-597 cuccuccaggagacggaucTT 456 gauccgucuccuggaggagTT 457 25 ± 1 AD-14579 caccuucugguaccagauc 637-655 caccuucugguaccagaucTT 458 gaucugguaccagaaggugTT 459 25 ± 1 AD-14580 cuucugguaccagaucgcg 640-658 cuucugguaccagaucgcgTT 460 cgcgaucugguaccagaagTT 461 42 ± 2 AD-14581 uucugguaccagaucgcgc 641-659 uucugguaccagaucgcgcTT 462 gcgcgaucugguaccagaaTT 463 56 ± 2 AD-14582 gguuauuuccgugggauac 667-685 gguuauuuccgugggauacTT 464 guaucccacggaaauaaccTT 465 19 ± 2 AD-14583 accucagcuuucccucgag 740-758 accucagcuuucccucgagTT 466 cucgagggaaagcugagguTT 467 40 ± 4 AD-14584 ccucagcuuucccucgagg 741-759 ccucagcuuucccucgaggTT 468 ccucgagggaaagcugaggTT 469 47 ± 5 AD-14585 uaccuuuugccgggagacc 766-784 uaccuuuugccgggagaccTT 470 ggucucccggcaaaagguaTT 471 102 ± 7  AD-14586 ccaugccgcccuccgggcu 866-884 ccaugccgcccuccgggcuTT 472 agcccggagggcggcauggTT 473 54 ± 3 AD-14587 acuauccaccugcaagacu 954-972 acuauccaccugcaagacuTT 474 agucuugcagguggauaguTT 475 22 ± 2 AD-14588 cuauccaccugcaagacua 955-973 cuauccaccugcaagacuaTT 476 uagucuugcagguggauagTT 477 14 ± 1 AD-14589 guccaagcugcggcucgcc 1029-1047 guccaagcugcggcucgccTT 478 ggcgagccgcagcuuggacTT 479 31 ± 2 AD-14590 cgagccugaggccgacuac 1158-1176 cgagccugaggccgacuacTT 480 guagucggccucaggcucgTT 481 16 ± 1 AD-14591 ugguggaaacccacaacga 1205-1223 ugguggaaacccacaacgaTT 482 ucguuguggguuuccaccaTT 483 98 ± 4 AD-14592 acccacaacgaaaucuaug 1213-1231 acccacaacgaaaucuaugTT 484 cauagauuucguuguggguTT 485 14 ± 1 AD-14593 ucaagcagaguacacacag 1238-1256 ucaagcagaguacacacagTT 486 cuguguguacucugcuugaTT 487 67 ± 8 AD-14594 cagaguacacacagcauau 1243-1261 cagaguacacacagcauauTT 488 auaugcuguguguacucugTT 485  9 ± 1 AD-14595 ucuucaacacaucagagcu 1268-1286 ucuucaacacaucagagcuTT 490 agcucugauguguugaagaTT 491 23 ± 3 AD-14596 gcgguaccugaacccgugu 1294-1312 gcgguaccugaacccguguTT 492 acacggguucagguaccgcTT 493 33 ± 2 AD-14597 cugcugaggcucaaguuaa 1336-1354 cugcugaggcucaaguuaaTT 494 uuaacuugagccucagcagTT 495  8 ± 1 AD-14598 gcgauaccucagcaaccgg 1404-1422 gcgauaccucagcaaccggTT 496 ccgguugcugagguaucgcTT 497 15 ± 0 AD-14599 ggcacccagcgacucgcca 1428-1446 ggcacccagcgacucgccaTT 498 uggcgagucgcugggugccTT 499 20 ± 2 AD-14600 ccagcgacucgccagagug 1433-1451 ccagcgacucgccagagugTT 500 cacucuggcgagucgcuggTT 501 17 ± 2 AD-14601 gagugguuaucuuuugaug 1447-1465 gagugguuaucuuuugaugTT 502 caucaaaagauaaccacucTT 503 13 ± 1 AD-14602 uugugcggcagugguugag 1475-1493 uugugcggcagugguugagTT 504 cucaaccacugccgcacaaTT 505 132 ± 9  AD-14603 ugugacagcagggauaaca 1540-1558 ugugacagcagggauaacaTT 506 uguuaucccugcugucacaTT 507 16 ± 3 AD-14604 acagcagggauaacacacu 1544-1562 acagcagggauaacacacuTT 508 aguguguuaucccugcuguTT 509 19 ± 1 AD-14605 cagcagggauaacacacug 1545-1563 cagcagggauaacacacugTT 510 caguguguuaucccugcugTT 511 34 ± 2 AD-14606 uaacacacugcaaguggac 1554-1572 uaacacacugcaaguggacTT 512 guccacuugcaguguguuaTT 513 76 ± 2 AD-14607 guucacuaccggccgccga 1581-1599 guucacuaccggccgccgaTT 514 ucggcggccgguagugaacTT 515 23 ± 1 AD-14608 uggccaccauucauggcau 1607-1625 uggccaccauucauggcauTT 516 augccaugaaugguggccaTT 517 19 ± 1 AD-14609 cauucauggcaugaaccgg 1614-1632 cauucauggcaugaaccggTT 518 ccgguucaugccaugaaugTT 519 24 ± 2 AD-14610 cagcaucugcaaagcuccc 1672-1690 cagcaucugcaaagcucccTT 520 gggagcuuugcagaugcugTT 521 17 ± 2 AD-14611 gcaaagcucccggcaccgc 1680-1698 gcaaagcucccggcaccgcTT 522 gcggugccgggagcuuugcTT 523 73 ± 5 AD-14612 ggagaagaacugcugcgug 1734-1752 ggagaagaacugcugcgugTT 524 cacgcagcaguucuucuccTT 525 13 ± 0 AD-14613 gaagaacugcugcgugcgg 1737-1755 gaagaacugcugcgugcggTT 526 ccgcacgcagcaguucuucTT 527 62 ± 4 AD-14614 gcuggaaguggauccacga 1787-1805 gcuggaaguggauccacgaTT 528 ucguggauccacuuccagcTT 529 12 ± 1 AD-14615 uuuggagccuggacacgca 1853-1871 uuuggagccuggacacgcaTT 530 ugcguguccaggcuccaaaTT 531 35 ± 1 AD-14616 uuggagccuggacacgcag 1854-1872 uuggagccuggacacgcagTT 532 cugcguguccaggcuccaaTT 533 76 ± 7 AD-14617 gccgugcugcgugccgcag 1926-1944 gccgugcugcgugccgcagTT 534 cugcggcacgcagcacggcTT 535 71 ± 5 AD-14618 uguccaacaugaucgugcg 2003-2021 uguccaacaugaucgugcgTT 536 cgcacgaucauguuggacaTT 537 41 ± 2 AD-14619 cugcggaucucugugucau 2179-2197 cugcggaucucugugucauTT 538 augacacagagauccgcagTT 539 76 ± 7 AD-14620 gcacuauuccuuugcccgg 2282-2300 gcacuauuccuuugcccggTT 540 ccgggcaaaggaauagugcTT 541 89 ± 9 AD-14621 ccggccucccgcaaagacu 476-494 ccggccucccgcaaagacuTT 542 agucuuugcgggaggccggTT 543 48 ± 3 AD-14622 cuacuggugcugacgccug 919-937 cuacuggugcugacgccugTT 544 caggcgucagcaccaguagTT 545 14 ± 1 AD-14623 auucauggcaugaaccggc 1615-1633 auucauggcaugaaccggcTT 546 gccgguucaugccaugaauTT 547 103 ± 6  AD-14624 aacugcugcgugcggcagc 1741-1759 aacugcugcgugcggcagcTT 548 gcugccgcacgcagcaguuTT 549 82 ± 3 AD-14625 cggaggaaggagucgccga 145-163 cggaggaaggagucgccgaTT 550 ucggcgacuccuuccuccgTT 551 47 ± 3 AD-14626 ggagcgggaggagggacga 236-254 ggagcgggaggagggacgaTT 552 ucgucccuccucccgcuccTT 553 31 ± 1 AD-14627 gcccucgggagucgccgac 457-475 gcccucgggagucgccgacTT 554 gucggcgacucccgagggcTT 555 56 ± 6 AD-14628 uuucuccuccaggagacgg 576-594 uuucuccuccaggagacggTT 556 ccgucuccuggaggagaaaTT 557 90 ± 3 AD-14629 ucgaggcccuccuaccuuu 754-772 ucgaggcccuccuaccuuuTT 558 aaagguaggagggccucgaTT 559 25 ± 2 AD-14630 uacuggugcugacgccugg 920-938 uacuggugcugacgccuggTT 560 ccaggcgucagcaccaguaTT 561 34 ± 2 AD-14631 gacuauccaccugcaagac 953-971 gacuauccaccugcaagacTT 562 gucuugcagguggauagucTT 563 24 ± 3 AD-14632 uacaacagcacccgcgacc 1108-1126 uacaacagcacccgcgaccTT 564 ggucgcgggugcuguuguaTT 565 113 ± 4  AD-14633 ugcugaggcucaaguuaaa 1337-1355 ugcugaggcucaaguuaaaTT 566 uuuaacuugagccucagcaTT 567  8 ± 1 AD-14634 ccugugacagcagggauaa 1538-1556 ccugugacagcagggauaaTT 568 uuaucccugcugucacaggTT 569 14 ± 1 AD-14635 auaacacacugcaagugga 1553-1571 auaacacacugcaaguggaTT 570 uccacuugcaguguguuauTT 571 18 ± 1 AD-14636 uauugcuucagcuccacgg 1717-1735 uauugcuucagcuccacggTT 572 ccguggagcugaagcaauaTT 573 109 ± 5  AD-14637 gcuguccaacaugaucgug 2001-2019 gcuguccaacaugaucgugTT 574 cacgaucauguuggacagcTT 575 29 ± 1 AD-14638 gucuccaucccugacguuc 2214-2232 gucuccaucccugacguucTT 576 gaacgucagggauggagacTT 577  75 ± 11 ¹a, g, c, u: ribonucleotide 5′-monophosphates (except where in 5′-most position, see below); T: deoxythymidine 5′-monophosphate; all sequences given 5′ → 3′; due to synthesis procedures, the 5′-most nucleic acid is a nucleoside, i.e. does not bear a 5′-monophosphate group 

1. A method of reducing the levels of a TGF-beta mRNA in a cell of a subject, or of TGF-beta protein secreted by a cell of a subject, comprising the step of administering an iRNA agent to said subject, wherein the iRNA agent comprises an antisense strand consisting of 15 to 30 nucleotides and having at least 15 or more contiguous nucleotides complementary to a mammalian TGF-beta mRNA, and a sense strand consisting of 15 to 30 nucleotides and having at least 15 or more contiguous nucleotides complementary to said antisense strand.
 2. The method of claim 1 wherein said iRNA agent mediates the cleavage of a TGF-beta mRNA within the target sequence of an iRNA agent selected from the group of: AL-DP-6837 to AL-DP-6864 and AD-14419 to AD-14638
 3. The method of claim 1 wherein said iRNA agent comprises 15 or more contiguous nucleotides from an iRNA agent selected from the group of: AL-DP-6837 to AL-DP-6864, AL-DP-6140 to AL-DP-6151, AL-DP-6262 to AL-DP-6277 and AD-14419 to AD-14638.
 4. The method of claim 1 wherein said iRNA agent is one of the iRNA agents selected from the group of: AL-DP-6837 to AL-DP-6864, AL-DP-6140 to AL-DP-6151, AL-DP-6262 to AL-DP-6277 and AD-14419 to AD-14638.
 5. The method of claim 1, wherein said iRNA agent is administered to a subject.
 6. The method of claim 5, wherein said administration comprises pulmonary administration.
 7. The method of claim 1, wherein the level of TGF-beta protein and/or TGF-beta mRNA is reduced by at least 20%.
 8. An isolated iRNA agent, comprising an antisense strand consisting of 15 to 30 nucleotides and having at least 15 or more contiguous nucleotides complementary to a mammalian TGF-beta mRNA, and a sense strand consisting of 15 to 30 nucleotides and having at least 15 or more contiguous nucleotides complementary to said antisense strand.
 9. The iRNA agent of claim 8, wherein said iRNA agent mediates the cleavage of a TGF-beta mRNA within the target sequence of an iRNA agent selected from the group of: AL-DP-6837 to AL-DP-6864 and AD-14419 to AD-14638.
 10. The iRNA agent of claim 8, wherein said iRNA agent comprises 15 or more contiguous nucleotides from an iRNA agent selected from the group of: AL-DP-6837 to AL-DP-6864, AL-DP-6140 to AL-DP-6151, AL-DP-6262 to AL-DP-6277 and AD-14419 to AD-14638.
 11. The method of claim 1 wherein said iRNA agent is one of the iRNA agents selected from the group of: AL-DP-6837 to AL-DP-6864, AL-DP-6140 to AL-DP-6151, AL-DP-6262 to AL-DP-6277 and AD-14419 to AD-14638.
 12. The iRNA agent of claim 8, wherein the iRNA agent further comprises a non-nucleotide moiety.
 13. The iRNA of claim 8, wherein the sense and/or antisense strand is stabilized against nucleolytic degradation.
 14. The iRNA agent of claim 8, further comprising at least one 3′-overhang wherein said 3′-overhang comprises from 1 to 6 nucleotides.
 15. The iRNA agent of claim 8, further comprising a phosphorothioate at the first intemucleotide linkage at the 5′ end of the antisense and/or sense sequence.
 16. The iRNA agent of claim 15, further comprising a phosphorothioate at the first internucleotide linkage at the 3′ end of the antisense and/or sense sequence.
 17. The iRNA agent of claim 8, further comprising a 2′-modified nucleotide.
 18. The iRNA agent of claim 17, wherein the 2′-modified nucleotide comprises a modification selected from the group consisting of: 2′-deoxy, 2′-deoxy-2′-fluoro, 2′-O-methyl, 2′-O-methoxyethyl (2′-O-MOE), 2′-O-aminopropyl (2′-O-AP), 2′-O-dimethylaminoethyl (2′-O-DMAOE), 2′-O-dimethylaminopropyl (2′-O-DMAP), 2′-O-dimethylaminoethyloxyethyl (2′-O-DMAEOE), and 2′-O-N-methylacetamido (2′-O-NMA).
 19. A method of reducing the levels of a TGF-beta mRNA in a cell, or of TGF-beta protein secreted by a cell, comprising contacting the cell with an iRNA agent of claim
 8. 20. A vector encoding an iRNA agent of claim
 8. 21. A cell comprising an iRNA agent of claim 8 or a vector of claim
 20. 22. A method of making an iRNA agent of claim 8, the method comprising the synthesis of the iRNA agent, wherein the sense and antisense strands comprise at least one modification that stabilizes the iRNA agent against nucleolytic degradation.
 23. A pharmaceutical composition comprising an iRNA agent of claim 8 and a pharmaceutically acceptable carrier.
 24. A method of treating a human diagnosed as having or at risk for developing a disease or disorder associated with undesired TGF-beta signaling, comprising administering to a subject in need of such treatment a therapeutically effective amount of an iRNA agent of claim
 8. 25. The method of claim 24, wherein the human is diagnosed as having or at risk for having idiopathic pulmonary fibrosis, diabetic nephropathy or chronic liver disease. 